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INTRODUCTION 
 
                     Ovarian cancer is the most lethal tumor of all 
gynaecological malignancies. It is the fifth most common tumor of 
women.  The case fatality rate is high with ovarian tumor than any 
other  gynaecological malignancies. 
Ovarian cancer is often asymptomatic and often  present  in late 
stages  in which the 5 year survival rate is poor. Hence early diagnosis 
and appropriate treatment is essential for the better outcome of the 
patients. 
Despite the great advancement in medicine,  the  prognosis  has 
not changed over periods. This is because of delay in the diagnosis of 
malignancy. 
The 5 year survival rate for stage 1 is 86%  and  with stage 2 is 
19% according  to FIGO 2006.The most common clinical symptoms 
are vague and non specific .  Majority of women presents with pelvic 
masses. Since ovarian cancer is the deadliest tumor, screening and 
providing appropriate therapy at the earliest possible is of  importance. 
2 
 
      The suboptimal primary cytoreductive surgery has great 
prognostic significance. The reason for this is due to inappropriate pre 
operative evaluation, which dictates the nature of the surgery to be 
performed and the experience of the surgeons in performing the 
staging Laparatomy, if indicated. Hence it is important for the 
gynaecologists to differentiate benign from malignancy in patients 
presenting with adnexal masses. 
Various studies have shown that the diagnosis of ovarian tumor 
by investigations like Ultrasonagram, Doppler, MRI, CT has been 
proved to be uncertain despite the need for expertise and they are not 
cost effective. 
In 1990, Jacob et al [18] developed a simple scoring index, Risk 
of malignancy index based on the menopausal status, ultrasound score 
and CA 125 value   which were obtained preoperatively. They 
concluded that RMI is very effective in discriminating benign and 
malignant ovarian mass. Later in 1996, Tingulstad et al [19] modified 
the RMI and named as RMI 2 and further it was modified as RMI 3 [20] 
in 1999. Yamamoto et al [24] developed a new RMI and named as RMI 
4 in 2009 where he included tumor size score. 
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The purpose of the present study was to assess the ability of 
Risk of malignancy index scoring system in differentiating benign and 
malignant ovarian tumors and to compare the scoring patterns with 
Histopathological findings. 
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AIM OF THE STUDY 
 
To evaluate the risk of malignancy index based on CA125, 
menopausal status and ultrasound score in women with ovarian mass. 
To arrive at an optimal cut off point of RMI score. 
To evaluate the performance of individual parameters and RMI 
in differentiating benign and malignant ovarian tumors. 
To validate the efficiency of risk of malignancy index in 
discriminating benign and malignant ovarian tumors 
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REVIEW OF LITERATURE 
 
The greatest clinical challenge among all gynaecological 
malignancies is the ovarian cancer.  56 – 60 yrs of age is the peak 
incidence of ovarian malignancy. 30%  of ovarian tumor  in  
postmenopausal women and  7%  in premenopausal women were 
malignant. The ovarian cancer constitutes sixth most common cancer 
in women and comprises 7.5 %  of  all  gynaecological  malignancies 
and  3.5% of all cancers in general in women.  
 
The incidence is 5.2 per 1,00,000 population.  
 
It was estimated that surgical procedure for a suspected ovarian 
tumor was performed in 5-10% of women in their life time. Among 
these, ovarian malignancy has been found in 13-21% of the women. In 
majority of pelvic masses,    80% are benign and only 20% are frankly 
malignant. Therefore it is of great importance to discriminate the 
benign and malignant tumor preoperatively and to reduce the number 
of surgeries performed in self limiting conditions.  
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In order to plan whether the ovarian tumor requires minimally 
invasive  procedures or extensive staging procedures, the gynecologist 
should  predict  the  presence  of  malignancy preoperatively. In 
women with adnexal masses, the optimal intervention depends upon 
the  evidence of malignancy.  
 
The ovary is composed of coelomic epithelial layer, germ cell 
layer and stromal layer. Epithelial lesions account for 80% of the 
ovarian neoplasms and represent over 90% of ovarian carcinoma. 
Serous lesion accounts for 70% of epithelial tumors and mucinous 
20%, endometroid 2%, clear cell, Brenner and undifferentiated 
carcinoma each represent less than 1% of epithelial lesions. Serous 
papillary cystadenocarcinoma is the dominant cell type in malignant 
tumors. Non epithelial malignancy account for 10% of all ovarian 
tumors and varies widely with age. The most important factor limiting 
the diagnostic specificity is the overlap of sonographic features.  
 
In the early stage of malignancy, the  majority of women with 
ovarian  mass  are  asymptomatic, often present with vague and 
nonspecific symptoms. The  presence  of  vague symptoms, especially 
in  premenopausal women  and  postmenopausal women like 
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dyspepsia, early satiety, loss of appetite, urinary urgency and / or 
frequency, altered bowel habits that are present  for less than 1 year 
duration or their persistence for more than 12 days per month  should  
alert  the  treating  physician. The ovarian mass in the reproductive age 
group are mostly functional and can be managed conservatively   or 
with minimal invasive procedures. For the ovarian mass occurring in 
premenopausal women and postmenopausal  women,  the  possibility  
of  malignancy is high and should  be  properly investigated and the 
probability of malignancy should be evaluated. A careful history 
taking regarding the presenting complaints, the nature, onset and 
progression  should be sought. The family history of malignancy such 
as breast cancer, colon cancer, ovarian cancer should  be  elicited , as 
10% of ovarian tumors runs in families. These familial carcinomas are 
associated with BRCA gene. Hereditary ovarian cancers are associated 
with HNPCC, Breast  ovarian  cancer syndromes.  
 
 A careful physical examination is essential to arrive at a clinical 
diagnosis.  If there is any suspicion of pelvic masses, imaging studies 
are advocated. The Ultrasonagram is the preliminary study in patients 
with pelvic adnexal masses.  Ultrasonagram is more commonly used 
to differentiate between benign and malignant ovarian tumor. The 
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ultrasonographic feature that are suggestive of malignancy are the 
following.  
1. Multiloculated lesion 
2. Bilateral lesion 
3. Ovarian volume more than 10cm3 
4. Septal thickness more than 2mm 
5. Cyst wall thickness more than 3mm 
6. Solid component / complex mass (Solid & Cystic)  
7. Papillary excrescences  
8. Increase in vascularity 
9. Doppler resistance index less than 0.40 (RI < 0.40) 
10. Presence of ascites 
11. Presence of intrabdominal metastasis 
 
The sensitivity of USG is high but the specificity is low for 
diagnosis of early ovarian malignancy. 
 
In 1993, Granberg et al [46] proposed a morphological 
classification based of ultrasonography. The percentage of malignancy 
in unilocular cyst was 0.3%, unilocular cyst with solid component was 
7%, multilocular lesion was 36%  and  solid  tumor  was  39%. 
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In 1991, Sassone et al [7] developed a scoring system based on 
the ultrasonographic  features like  structure  of  internal wall, 
thickness of the wall, the presence of septations and  echogenicity.  
 
De Priest et al[57], 1993 combined tumor volume, wall structure 
and septal structure. In a study of 121 sonogram  of  patients  with 
ovarian mass ,  they  found  that  80 patients with ovarian tumor with a 
score of less than 5 were benign.  
 
 In 1995, Botta  and Zarcone  compared the diagnostic accuracy 
of the Sassone [7]  and  De priest[57]  scoring  systems. They  found  
that  cut off  value of 9 in  Sassone[7]   scoring system and cut off  
value of  5  in De priest57 score  has a  large  number  of  false  positive  
results. There were considerable overlap  in their  scores of benign and 
malignant tumors. They concluded that the accuracy of scoring system 
was not improved by the addition of ovarian volume as a criteria. 
 
 Ferrazzi et al (1997) [45] in a prospective comparison of the 
morphological scoring system, a new multicenter score demonstrated 
a statistically significant diagnostic accuracy. This was due to addition 
of two new criteria that allowed correction for typical dermoids  and  
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endohaemorrhagic corpora lutea.  The scores were sensitive but not 
specific with the best diagnostic accuracy of 72% obtained with a 
sensitivity 87%  and specificity  67%. This study gave better result 
than other previous scoring system (Sassone et al 1991[7], Granberg  et 
al[46]  1993 etc) in predicting the malignancy.  
 
 None of these scoring systems have very high accuracy. The 
parameter used in different ultrasonography morphological scoring 
system needs specific expertise skills of  the  sonologist.     
 
CA 125 is  the  most  commonly  used tumor marker in 
screening of  high risk  patients  with ovarian tumor. CA 125 also 
called  as cancer Antigen 125, was so named  because  it  was the 
125th  antibody  found while  testing  various  antibodies against  
ovarian  tumor. Normal level is 0-35 U/ml. CA 125 was first described 
by Bast and collegues in 1983. 
 
 CA 125  is  produced  in  low  quantities  by  normal ovarian 
epithelial cells, peritoneal  lining  cells, lining cells of  GIT, pancreas, 
breast  and  lung. Thus an elevated level of CA 125 is not very 
specific. 
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High levels of CA 125 are frequently associated with ovarian 
malignancy. However due to low sensitivity and specificity, CA 125 
was not useful as a screening method.  
 
CA 125 is found to be elevated besides in ovarian malignancy 
like breast cancer, lung cancer, GIT Carcinomas, pancreatic cancer, 
Endometrial cancer, fallopian tube cancer etc. The benign conditions 
associated with elevated CA 125 levels are endometriosis, fibroid 
uterus, Pelvic inflammatory disease, menstruation, Pregnancy, ectopic 
pregnancy and other non gynecological conditions like peritonitis, 
diverticulitis, inflammatory bowel disease, tuberculosis, liver disease, 
recent surgery etc.  
 
The low specificity of CA 125 values demonstrates that CA 125 
is not specific for ovarian cancer especially in reproductive age, where 
the various benign conditions associated with elevated CA 125 levels 
are more common. Hence the cut off value of CA 125 in 
postmenopausal women in predicting malignancy is 35U/ml whereas 
in premenopausal women, the cut off value upto 200 U/ml is not very 
predictive. 
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The sensitivity of the CA 125 value was limited in early stage 
of the malignancy. Also not all malignant ovarian cancer was 
associated with elevated CA 125 levels thus lowering the sensitivity of 
the CA 125.  
 
Serum CA 125 levels are measured in the blood by second 
generation test. Due to poor sensitivity and specificity, CA 125 values 
are not useful in screening the general population. However high risk 
women should be subjected to CA 125 test.  
 
CA 125 is very useful in detecting the treatment outcome in 
women with ovarian cancer. Serial CA 125 test predicts the recurrence 
of ovarian tumor at the earliest. Also CA 125 has a role in predicting 
the treatment effectiveness of patients with ovarian cancer undergoing 
chemotherapy.    
 
The various other tumor markers that can used for screening of 
ovarian cancer are CA 19-9, CA 15-3, lipid  associated  sialic acid, 
osteopontin etc., None of these tumor marker have diagnostic 
potential.  
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 A new approach in the diagnosis of ovarian cancer is the 
proteomic pattern which detects the proteins & protein fragments 
circulating in the blood. The sensitivity of proteomic pattern is 100% 
and specificity is 95% with positive predictive value of 94%. But its 
efficacy and the validation is yet to be studied in large population.  
 
Genetic testing is advocated in women with family history of 
epithelial ovarian cancer.     
  
There are numerous investigational modalities that are being 
used and studied. None of them proved to be a best in differentiating 
benign and malignant ovarian tumors. Hence was introduced a 
multimodal screening modalities, which combines various parameters 
to improve the sensitivity and specificity of the test in predicting the 
presence of malignancy.  
 
In 1990, Jacob et al [18] developed a new scoring system called 
Risk of Malignancy index (RMI). RMI is based on the following 3 
parameters. 
1) Serum CA 125 level (U/ml) 
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2) Ultrasound score. The various parameters are multilocular cyst, 
presence of solid mass, bilateral lesions, evidence of metastasis, 
presence of ascites. Each parameter is given 1 point. The 
ultrasound  score (U)  of  O is given if  the total point is O, 
score of  1  if  the  total  point is 1 and  score of 3 if the total 
point is between 2-5. 
3) The menopausal status (M) M=1 if premenopausal and M-3 if 
postmenopausal.  
 
RMI is calculated with these 3 criteria. It is the product of CA 
125 level (absolute value U/ml), menopausal score and ultrasound 
score. It is expressed as,  
RMI = U x M x CA 125 
 Using RMI cut off level of 200, the sensitivity is reported as 
85% and specificity as 97% for diagnosing ovarian cancer.  
 
 In 1993, Davis et al [22] performed a study on 124 patients to 
validity the Risk of malignancy index. The study confirmed that the 
RMI is more appropriate in differentiating benign and malignant 
tumor than the individual criteria and the results were compared with 
the other scoring systems. In this study, the sensitivity of RMI was 
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87% and specificity was 89%. It was concluded that RMI is a simple 
scoring system that can be employed in clinical practice for 
discriminating begin ovarian mass from malignant lesion and provides 
an opportunity for appropriate selection of cases that can be referred to 
tertiary centre, where appropriate surgery by expert surgeons are 
available.  
 
 Tingulstad et al[19]  in 1996 modified the risk of malignancy 
index proposed by Jacob et al [18] in 1990 now called as RMI 1. The 
RMI 2 of Tingulstad et al [19] was calculated based on the same 
parameters as Jacob et al [18] but the scoring value was altered.  
1. CA 125 level (value in U/ml) 
2. menopausal score M (M=1 if premenopausal but M = 4 if 
postmenopausal)    
3. Ultrasound score U (based on 5 USG features like bilateral 
lesion, multiloculation, solid lesion, ascites and extra ovarian 
metastasis. Each parameters were given 1 point and U=1 if the 
points were 0 or 1 and U = 4 if two or more parameters were 
present).  
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RMI is the product of CA 125, Ultrasound score and 
menopausal status. The sensitivity of RMI 2 was 71%, specificity was 
96%, positive predictive value was 89% and negative predictive value 
was 88%. They concluded that RMI 2 has better performance than 
RMI 1 and recommended that RMI 2 is better than RMI 1 in 
discriminating benign and malignant ovarian tumors. 
 
In 1999, Tingulstad et al [20] further modified RMI 2 previously 
modified from RMI 1 by altering the scoring values and it is now 
termed as RMI 3. The RMI 3 is the product of ultrasound score, CA 
125 value and menopausal status but the scoring is different from RMI 
1 and RMI 2. The CA 125 value is the absolute value. The 
menopausal score is like RMI 2, that is M=1 if premenopausal and 
M=3 if postmenopausal. The ultrasound score U is based on the same 
five criteria like bilateral lesion, multiloculations, presence of solid 
areas, ascites and intra abdominal metastasis. U=1 if no or one criteria 
is present and U=3 if two or more criteria is present. 
 
The study was conducted in 365 patients with a cut off value of 
200, the sensitivity of RMI 3 was 71.1%, specificity was 92%, 
positive predictive value was 69% and negative predictive value was 
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92%. They concluded that RMI 3 has high sensitivity and specificity 
in diagnosing ovarian cancer. They reported that RMI scoring system 
had better performance than individual parameter in discriminating 
ovarian tumor as benign or malignant. 
 
In 1999, Morgante et al [23] tested these RMI indices in 124 
patients with ovarian mass and showed that risk of malignancy index 
was a simple scoring system that are clinically applicable and aids in 
discriminating benign from malignant ovarian mass. They compared 
RMI 1 and 2 and found that RMI has better performance in detecting 
malignancy than individual criteria. 
 
Risk of malignancy index was further modified by Yamomoto 
et al [24] in 2009.  They introduced new criteria in RMI score. It is the 
tumor size score. According to them, RMI 4 is the product of CA 125 
level, ultrasound score, and menopausal status and tumor size score. 
 RMI 4 = CA 125 x U x M x S. 
Where, CA 125 level – the absolute value in U/ml 
          U is the ultrasound score based on the 5 parameters- bilateral 
lesions, multilocularity, solid areas, ascites and extra ovarian tumor. 
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U=1 if no or one parameter is present and U = 4 if 2 or more 
parameter is present.  
S corresponds to tumor size score. Where S =1, if tumor size is 
less than 7 cm in a single largest diameter and S=2 if tumor size  is 7 
cm or more. The study showed that inclusion of tumor size score 
improved the efficiency of the RMI to diagnose malignancy. They 
compared the four malignancy indices and showed that RMI 4 has 
better sensitivity and specificity in differentiating malignant and 
benign ovarian tumors. They showed that while using RMI 4, the cut 
of value is 450. The sensitivity of RMI 4 was 86.8%, specificity was 
91%, positive predictive value was 97.5% and negative predictive 
value was 90%. Thus they concluded that RMI 4 was better than RMI 
1, 2 and 3.  
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There are four risk of malignancy index scoring system. 
 
 
Parameters RMI 1 RMI 2 RMI 3 RMI 4 
 
1. 
 
CA 125 
 
U/ml 
 
U/ml 
 
U/ml 
 
U/ml 
 
2. 
 
Menopausal Status 
- Premenopausal  
- Postmenopausal  
 
 
1 
3 
 
1 
4 
 
1 
3 
 
1 
4 
 
3. 
 
Ultrasonogram  score 
If no parameter present 
If  1 parameter  
If  2 or more parameters 
 
U = 0 
U = 1 
U = 3 
 
 
U=1 
U=1 
U=4 
 
 
U=1 
U=1 
U=3 
 
U=1 
U-1 
U=4 
 
4. 
 
Tumor size score  
 size <7cm 
 size >7cm 
 
 
- 
- 
 
 
- 
- 
 
 
- 
- 
 
 
S = 1 
S = 2 
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In 2001, Manjunath et al [25] conducted a study that compared 
the ability of Risk of Malignancy indices RMI 1, 2 and RMI 3 in 
discriminating benign and malignant ovarian tumor. The study showed 
that there was no statistical difference in all three RMI indices in 
differentiating benign and malignant ovarian tumors. They concluded 
that diagnostic performance of the RMI indices RMI 1, RMI 2 and 
RM1 3 were reliable.  
 
Twickler et al [17] in 1999 devised “The Ovarian Tumor index’ 
to predict the risk for malignancy. They studied 244 women, 214 had 
benign lesions and 30 had malignant lesions. They concluded that by 
combining various parameters like age in years, ovarian volume, 
Sassone`s[7] morphology score, PI, central or septal location, 
peripheral location and echogenicity, the ovarian tumor index is found 
to be accurate in predicting the ovarian malignancy. Torres et al[56] 
(2002) conducted a study on 158 patients with ovarian mass and 
showed that the sensitivity of RMI calculated was 73% and had a 
specificity of 86%.  
Ma et al (2003) performed a study on 140 patients to evaluate 
the Risk of Malignancy index preoperatively in women with pelvic 
21 
 
mass. The sensitivity of the RMI studied was 87.3%, specificity was 
84.4%, positive predictive value was 82.17% and negative predictive 
value was 89%. They concluded that, there was no statistically 
significant difference among RMI 1, 2, 3 in differentiating benign and 
malignant ovarian tumor and showed that RMI is reliable in predicting 
malignancy in preoperative evaluation of ovarian tumor. 
  
In 2003, Anderson et al [27] demonstrated the ability of RMI in 
discriminating benign and malignant ovarian tumor among 180 
patients. The sensitivity of RMI with cut off value 200 was 70.6%, the 
specificity was 87.7%, positive predictive value was 66.1% and 
negative predictive value was 89.8%.   
  
Obeidat et al [40] (2004) performed a study to analyse the 
validity of RMI in 100 women with ovarian mass. The RMI scoring 
system with a cut off value of 200 showed the sensitivity to be 90%, 
specificity 89%, positive predictive value 96% and negative predictive 
value 78%. They showed that RMI is a suitable scoring index. 
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In 2005, Leelahakorn et al [47] evaluated 175 women with pelvic 
adnexal masses. The RMI was calculated preoperatively and was 
confirmed with histopathology post operatively. With a cut off value 
of 200, the sensitivity, specificity, positive predictive value and 
negative predictive value of the RMI were 88.6%, 90.7% 70.5% and 
97% respectively. In this study, the Ultrasound scoring system of 
Ferrazzi et al [45] was used in the calculation of RMI. They concluded 
that RMI is a simple, reliable scoring method. 
 
Ulusoy et al [49] (2007) assessed 296 patients with RMI. The cut 
off value for RMI was 200. The sensitivity was 71.7% specificity was 
80.5%, the positive predictive value was 67.3% and negative 
predictive value was 83.6%. With a cut off value of 153 the diagnostic 
rate of RMI was 79.4%. 
 
In 2010, van den Akker et al [31] conducted a study in 
Gynaecologic oncology in 548 patients to evaluate the RMI in daily 
basis. They showed with a cut off value of 200, RMI had a sensitivity 
of 81%, specificity 85%, positive predictive value 48% and negative 
predictive value 96%. They concluded that RMI is a simple scoring 
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system in diagnosing ovarian cancer during the preoperative 
evaluation.   
 
Rachmasari Putri et al (2010) analysed 90 patients 
retrospectively and calculated the Risk of Malignancy index score. 70 
patients had malignancy and 20 patients had benign tumors. The 
sensitivity of RMI in the study was 70%, specificity 75%, positive 
predictive value 90.74% and negative predictive value 41.67%, when 
the cut off value of RMI was 200. They concluded that RMI is very 
useful method in diagnosing malignancy. 
 
In 2011, Milan Terzic et al evaluate the ability of RMI scoring 
system to detect malignancy. The study involved 81 patients, out of 
which 51 had benign tumors and 30 had malignancy. With a cut off 
value of RMI 200, the sensitivity was 83.33%, specificity was 
94.12%, positive predictive value was 89.29% and negative predictive 
value was 90.57%.  
 
Monirath Hav et al [60] (2011) studied the effectiveness of RMI 
in primary evaluation of patients with adnexal masses. 151 patients 
were included in the study. 132 patients were diagnosed to have 
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benign mass and 19 were diagnosed to have malignant mass. The 
study showed that the best cut off value of RMI 3 was 238 at which 
the performance of RMI was good. The sensitivity was 89.5%, 
specificity was 96.2%, the positive predictive value was 77.3% and 
negative predictive value was 98.4%. 
 
In 2011, Bouzari Z et al studied the RMI Scoring in 182 patients 
to evaluate its ability to diagnose malignancy in patients with ovarian 
mass. The study showed at a cut off value of 200, the sensitivity, 
specificity positive predictive value and negative predictive value of 
the RMI were 91.3%, 88%, 52% and 98.5% respectively. They 
concluded that the sensitivity, specificity, positive predictive value and 
negative predictive value was high at a cut-off point of 265  in 
differentiating benign and malignant ovarian tumors. The cut-off point 
of 265 for the RMI was based on the Receiver operating characteristic 
curve evaluation at which the sensitivity was 91.3% and specificity 
was 96.2%.  
 
In 2012, Erfan Akturk[11] et al conducted a study to compare the 
ability of the four risk malignancy indices RMI 1, RMI 2, RMI 3 and 
RMI 4. The study included 100 patients with ovarian mass. They 
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proposed that performance of RMI 1, RMI 2 and RMI 3 at a cut off 
value of 200 and RMI 4 at the cut off value of 500 had better 
performance and there was no statistical difference. The sensitivity, 
specificity, positive predictive value, negative predictive value of RMI 
1, RMI 2, RMI 3, RMI 4 were obtained and there was no statistical 
difference and their diagnostic performance were same. They 
concluded that RMI was a simple index and any of the four RMI 
indices can be used even in unspecialised units. RMI is most useful 
diagnostic index in proper selection of patients who require referral to 
tertiary centres, and also differentiates benign disease that needs 
conservative line of management or minimal invasive procedures, thus 
aiding in the reduction of unnecessary surgical exploration of patient 
with benign diseases. The study showed that in preoperative 
evaluation of patients with ovarian tumor, the RMI should be the test 
of choice in discriminating benign and malignancy conditions.  
 
Wang et al [11] (2012) studied an improved risk of malignancy 
index on 180 women with ovarian tumor. He modified the RMI 
developed by Jacob et al [18] by introducing colour doppler study and 
new tumor marker (Tumor specific growth factor). He redesigned the 
RMI by including ultrasound sound score, Tumor specific growth 
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factor levels and colour doppler flow imaging result and calculated the 
improved RMI. The study concluded that improved RMI has high 
sensitivity, specificity, positive predictive value and negative 
predictive value when compared to RMI. The study showed that 
Improved RMI has better performance than the RMI of Jacob et al [18] 
in differentiating benign from malignant ovarian tumor. He showed 
that, in comparison of classic Jacob’s model the improved RMI was 
accurate in predicting germ cell tumor, granulosa cell tumor and 
ovarian malignancies in early stage. Thus with invention of 
sophisticated doppler methods which requires high level of expertise 
in ultrasonogram may be applicable in tertiary centre. 
 
In 2012, Hakansson F et al conducted a prospective 
observational study in the tertiary oncology centre including 1159 
patients with pelvic masses. The main objective of the study was to 
recalculate the RMI at tertiary centre and to assess the diagnostic 
ability of RMI with cut off value of 200 for preoperative diagnosis of 
ovarian cancer. The sensitivity of the RMI was 92% and specificity 
was 82%, positive predictive value was 62% and negative predictive 
value was 97%. Based on the study, he concluded that Risk of 
malignancy index has high diagnostic performance in differentiating 
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benign and malignancy tumor which enable the malignant patients to 
further preoperative investigations if needed. 
 
The adnexa refer to the ovaries and fallopian tubes. The human 
female gonads are the ovaries. The site of location of ovaries is on 
either side of uterine cornua attached to uterus by means of ovarian 
ligament. The blood vessels and nerves reach ovaries via the 
Infundibulopelvic ligaments which extend from ovary to the lateral 
pelvic wall. They are also known as suspensory ligament of ovary.  
The ovaries are attached to the broad ligament via the meso ovarium.  
 
The cut section of ovary shows outer cortex and inner medulla. 
The outer cortex has a specialised stroma and the follicles. It is lined 
by cuboidal surface epithelium derived from mesothelium of ovary. 
The ovarian medulla is composed of blood vessels and fibro muscular 
layer. 
 
The ovary is pearly white in colour due to the presence of tunica 
albuginea. Before menopause, each ovary measures about 3.5 X 2 X 
1.5 cm. In early menopause, the dimensions of each ovary is 2 X 1.5 X 
0.5 cm whereas in late menopause it measure about 1.5 X 0.75 X 5 
cm.  
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Each ovary is supplied by ovarian artery, a branch of abdominal 
aorta and ovarian branch of uterine arteries. The veins follow their 
respective arteries. The right ovarian vein drains into IVC and left vein 
drains into the left renal vein.  
 
The lymphatic’s of ovary follow the artery and drains into the 
paraaortic lymph nodes. The nerve supply is from the extension of 
renal plexus.  
 
The main function of the ovary is releasing of ovum during 
reproductive age and production of sex hormones namely estrogen and 
progesterone.  
 
In XX fetus, genital ridge develop on 5th week after fertilisation 
and primordial germ cell follicles are formed in the yolk sac. They 
migrate towards the genital ridge around 6th week of intrauterine life 
along the mesentery of hindgut. The genital ridge is formed from 
coelomic epithelium which differentiates into the pregranular cells. 
These cells surround the germ cells and are arranged in the ovarian 
cortex.  
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After menopause, the ovary shrinks and is reduced in size and 
volume. The tunica albugenia thickens. In early menopause the 
volume is 8 ml whereas in late menopause the volume is less than 2 
ml.  
Due to the complexity in the development, the embryology and 
histology, the ovary is potential to develop malignancy. Due to its 
anatomic location deep in pelvis it is not easily accessible clinically 
for any screening procedures. 
 
The ovarian tumors can arise from epithelial cells, germ cells, 
stromal cells and connective tissue. About 80% of ovarian tumors are 
epithelial in origin. Among epithelial tumors, 80% are benign and 
20% are malignant. Among malignant ovarian tumors, 90% are 
epithelial in origin.  Also malignant ovarian neoplasms are primary 
tumor in 80% of cases and in 20%, they are secondary from GIT, 
breast and colon.  
 
The classification of ovarian tumor (benign and malignant) is 
devised by WHO and are broadly classified into Nine groups.   
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WHO CLASSIFICATION OF OVARIAN TUMORS 
I Epithelial tumors 
1. Serous tumor 
2. Mucinous tumor 
3. Endometroid tumor 
4. Clear cell tumor 
5. Brenner tumor 
6. Mixed epithelial tumors  
7. Undifferentiated Carcinoma  
8. Unclassified epithelial tumors.  
II Germ cell tumors 
1. Dysgerminoma  
2. Endodermal sinus tumor  
3. Embryonal carcinoma  
4. Polyembroyoma 
5. Choriocarcinoma  
6. Teratoma  
7. mixed forms  
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III Lipid (Lipoid) cell tumors  
IV Sex cord (Stromal) tumors 
1. Granulosa cell tumor 
2. Theca cell tumor 
3. Androblastomas: Sertoli leydig cell tumors 
4. Gynandroblastomas 
5. Unclassified.  
V. Gonadoblastomas  
 1. Pure  
 2. Mixed with dysgerminoma or other germ cell tumors  
VI  Soft tissue tumors not specific to ovary 
VII  Unclassified tumors 
VIII  Secondary (metastatic) tumors 
IX Tumor like conditions  
 The epithelial ovarian tumors arise from the mesothelial cell 
derived epithelial cells lining the surface of the ovary. They constitute 
80% of total ovarian tumors and 90% of malignant ovarian cancer. 
The most common epithelial tumor is papillary serous cystadenoma 
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and cystadenocarcinoma which accounts for 50% of the epithelial 
tumors.  
 
Borderline Ovarian Tumor: 
 It was first described by Taylor in 1927. It is also known as 
ovarian epithelial tumor of low malignant potential. Borderline tumor 
belongs neither to benign nor to malignant group and hence they are 
intermediate. Around 10-20% of epithelial tumors are borderline 
tumor. The borderline tumor shows cellular atypia, pseudo 
stratification, minimal mitotic activity (<4/HPF), papillary tufting. 
 
 There is no stromal invasion which differentiates Borderline 
from frank malignancy. The characteristic feature that is peculiar to 
Borderline tumor is that the patient has high survival rate as the 
disease follows indolent growth. Borderline tumor is diagnosed only 
on histopathological examination after studying multiple sections.  
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Serous Tumors: 
 These are the most common epithelial ovarian tumor 
constituting 50% of all epithelial tumors. About 60-70% are benign 
and 20-25% are frankly malignant and 15% are borderline. These 
tumors are cystic tumors, which are uniloculated or multiloculated 
contained clear straw coloured fluid. Papillary projections are 
presented in benign and coarse papillary growths are seen in papillary 
serous cystadenocarcinoma which is the commonest serous malignant 
tumor. The tumor is lined by tall columnar cells resembling the 
endosalphinx. Around 80% of benign serous tumors are potential for 
secondary malignant change.  
 
Mucinous tumor: 
 They constitute 15-25% of epithelial tumor. They are mostly 
unilateral and usually multiloculated cystic tumor. They grow to a 
large size reaching up to 30cm. The cyst wall is smooth and filled with 
thick mucinous fluid. These tumors may weigh as much 5-10kg. The 
cyst is lined by columnar mucin secreting epithelium that resembles 
the lining of endocervix.  The most of these tumors are benign.10-15% 
are borderline and only 5-10% constitute the malignant counterpart  
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Pseudomyxoma peritonei, results when the tumor ruptures and leads to 
dense adhesions.  
 
Endometroid tumors:  
 These are mostly solid tumor with cystic spaces lined by 
glandular epithelium which resembles the lining of the endometrium. 
Most of these tumors are malignant. They constitute for 20% of 
ovarian cancer. Endometriosis coexists in 15% cases whereas 
endometrial carcinoma coexists in 20% cases. 
 
Clear cell tumor: 
 It is also known as mesonephroid tumor. It is a rare tumor lined 
by large cuboidal epithelial cells resembling the mullerian derivatives. 
The characteristic feature of this highly malignant tumor is the 
presence of hobnail cells. 
 
Brenner tumor:  
 This is also known as transitional cell tumor. It is a rare tumor 
accounting for 2-3% of epithelial tumors. The tumor is mostly solid 
and is composed of transition cells and fibrous stoma. It is 
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characterised by the presence of “Walthard cell nests” The cells have 
puffed wheat appearance due to the presence of longitudinal groove. 
They are usually small in size. It is usually associated with mucinous 
tumor. Occasionally, pseudomeig syndrome presents with Brenner.  
 
Germ Cell Tumors:  
 They comprise around 15-20% of all ovarian tumors. Dermoid 
cyst or benign cystic teratoma accounts for 95% of germ cell tumors. 
Malignant germ cell tumors are more common in the first and second 
decade of life.  
 
Teratoma: 
 They arise from embryonic cell. They are of three types 
1) Mature teratoma (dermoid Cyst) – Benign  
2) Immature teratoma – Malignant 
3) Monodermal highly specialised tumor – struma ovarii 
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Benign cystic teratoma:  
 Benign cystic teratoma is also known dermoid cyst. It is the 
most common germ cell tumor occurring at all ages. It is usually 
unilateral and often asymptomatic. They are composed of cells of all 
three germ layers namely ectoderm, mesoderm and endoderm of 
which ectoderm cells predominate. They are cystic lesion with solid 
component. They are mostly filled with sebaceous material and inner 
wall shows hair, bone, teeth, cartilage etc derived from various germ 
layers. Embryonic node or focus is found in the inner wall. 
Ultrasonogram shows cystic mass with solid components. 1.7% of 
dermoid cysts can develop in to epidermal tumor. Sarcomatous change 
is very rare.    
 
Immature teratoma:  
 They constitute the second most common germ cell tumor. It is 
mostly unilateral. They are grossly large, lobulated or rounded mass. 
The microscopic picture shows variety of tissues including muscle 
tissue, intestinal mucosal cells, brain tissue, hair, sebaceous material 
etc. The neuroectoderm cells predominate and grading is based on 
immature neural element. Embryoma is defined as immature teratoma 
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which had a recognisable form of fetus. Sarcoma is more common and 
most of immature teratoma is malignant.  
 
Struma Ovarii : 
 They are the monodermal specialised tissue consisting of 
thyroid tissue. 5-8% of patients with struma ovarii have 
hyperthyroidism. The majority of the tumor consists of thyroid cells 
which would have developed at the expense of other tissues. Most 
commonly these tumors are benign but malignant transformation of 
thyroid cells resembling malignant thyroid tumor is   possible.  
 
Carcinoid: 
 It is another type of monodermal specialised tumor which is 
either primary or secondary. It is also known as Argentaffinoma. It is 
capable of secreting 5 hydroxy tryptamine which causes flushing and 
cyanosis.  
 
Dysgerminoma:  
 Dysgerminoma is the most common malignant germ cell tumor 
occurring in younger age group. They correspond to seminoma of 
testis. They are unilateral in most case and 15% cases are bilateral. 
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They are solid tumor composed of clear round cells. They secrete 
placental lactogen, Lactate dehydrogenase and B-HCG. They do not 
secrete sex hormones. Clear round cells with lymphocytic infiltration 
are characteristic feature of dysgerminoma. Dysgenetic gonad is 
notorious for the occurrence of dysgerminoma. Around 70% of these 
tumor are diagnosed early in stage 1. These tumors are highly radio 
sensitive. But due to their occurrence in younger age, radiation therapy 
damages the other ovary and questions the future fertility. They are 
usually conservatively managed by surgical methods, followed by 
chemotherapy if needed. 
  
Endodermal sinus tumor: 
 They are known as Yolk sac tumor. They are the second most 
common germ cell tumor. They are highly malignant tumor occurring 
in young children. They commonly present with pain abdomen and / 
or distension. It is a rapidly growing tumor arising from multipotential 
embryonal tissue. The yolk sac tumor secretes alphafetoprotein and 
alpha–1 antitrypsin. These are used as tumor markers and can be 
stained by immunoperoxidase technique. Though they are highly 
malignant with rapid growth, they are sensitive to chemotherapy.  
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Embryonal cell carcinoma: 
 Embryonal cell carcinoma is a highly malignant but rare form 
of germ cell tumor. The tumor secretes alphafetoprotein and chorionic 
gonodotrophin. It is most common in prepubertal age group. It 
presents with various symptoms like precocious puberty and menstrual 
irregularity.  
 
Choriocarcinoma:   
 Ovarian choriocarcinoma is very rare form of germ cell tumor. 
It is highly malignant with early widespread metastasis. The tumor 
elaborates HCG which is an ideal tumor marker. It is very rare in pure 
form, but can be seen in mixed forms. Unlike gestational 
choriocarcinoma, ovarian choriocarcinoma are not very much 
responsive to chemotherapy.  
 
Mixed Germ Cell Tumor: 
 Mixed germ cell tumor as name implies consists of two or more 
germ cell tumor. More than half of these tumor turns malignant.  
Sex Cord Stromal Tumor: 
 Sex cord stromal tumor arise from the sex cord, before they 
differentiate into male / female or from the ovarian stroma. They are 
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also known as mesenchymoma. These tumors are mostly functional, 
exerting feminising effect or virilizing effect based on the presence of 
female or male elements. 
 
Granulosa cell tumor: 
 It accounts for 2% of ovarian tumor. Granulosa cell tumor is the 
most common sex cord stromal tumor. It is a very slow growing 
tumor. It is a feminising tumor capable of producing estrogen. It arises 
from the granulosa cells that are not used in the formation of graffian 
follicle. Granulosa cell tumor can occur at any age and presenting 
symptom is based on the age of occurance of the granulosa cell tumor. 
Around 5% of Granulosa cell tumor occur in  prepubertal age group. 
They present with precocious puberty with development of secondary 
sexual characters like breast development, pubic hair, axillary hair 
development and menstruation. These patients are treated with 
unilateral salphingoopherectomy. Adult type Granulosa cell tumor, if 
occur in the child bearing age group they develop symptoms of 
abnormal uterine bleeding resembling metropathia hemorrhagica with 
development of cystic glandular hyperplasia secondary to excess 
estrogen. In postmenopausal women, granulosa cell tumor most 
41 
 
commonly presents with postmenopausal bleeding secondary to 
endometrial hyperplasia.  10-12% of women with granulosa cell tumor 
had concurrent endometrial carcinoma. The tumor is smooth lobulated 
, variable in size with cystic and solid components. On cut section due 
to lipid content it is yellow or orange in colour. Microscopically, the 
cells resemble granulosa cells with characteristic formation of Call 
Exner body.   Other pathognomonic feature of Granulosa cell tumor is 
the presence of coffee bean appearance.  
 
 The tumor cells are capable of secreting Inhibin which can be 
used as a tumor marker. The tumor after removal, are known for late 
recurrence. The peculiarity of the metastasis is that it first spreads to 
opposite ovary followed by lumbar region. The secondary metastasis 
deposit later develop in the liver, mesentry and the mediastinum. In 
around 20% of patients with feminisinig tumor, Endometrial 
carcinoma develops.  
 
Theca cell tumor: 
 Theca cell tumor is a rare sex cord stromal tumor. Thecoma 
classically affects postmenopausal women, who presents with 
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postmenopausal bleeding due to excess estrogen production. These 
patients are prone to develop endometrial hyperplasia and often have 
endometrial carcinoma. Thecoma is usually unilateral and cut section 
show lipid deposits. It resembles fibroma externally. Total abdominal 
hysterectomy with bilateral salphingoopherectomy is the treatment of 
choice in postmenopausal women. 
 
Arrhenoblastoma: 
 These are rare ovarian tumors. They are virilising 
mesenchymoma which secretes androgens and causing defeminisation 
and further producing masculinization. The women affected with 
arrhenoblastoma typically in child bearing age group develops 
alteration in body contour, flattening of breast, irregularity of 
menstrual flow resulting in amenorrhea. Later, when excess of 
androgens are secreted they develop cliteromegaly, hirsutism, 
coarsening of feature and finally with breakup of voice. The tumor is 
usually unilateral. The malignant potential is high with virilising 
tumor. Microscopically, the tumor shows seminiferous tubules. 
Clinically the endocrine behavior of the tumor clinches the diagnosis.  
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Gynandroblastoma: 
 The Gynandroblastoma typically has the characteristic of both 
Granulosa cell tumor and arrhenoblastoma combined together. It is 
very rare in occurrence. It is usually benign. 
 
Gonadoblastoma:    
 It is a very rare tumor which consists of gonadal stromal cells 
and germ cells. More than half of the patients with Gonadoblastomas 
has dysgerminoma.  
 
Ovarian Fibroma:  
 It is the most common tumor arising from the ovarian 
connective tissue. Ovarian fibroma accounts for 3% of ovarian 
neoplasms. They grow to a large size about 15cm in diameter and 
weighs as much as 25kg. The tumor is notorious for cystic 
degeneration. The ovarian fibroma is harder than uterine fibroid. It is  
encapsulated with dilated veins over the capsule. Histology shows 
spindle shaped cells which closely resembles the ovarian cortex 
spindle cells. Ovarian fibroma is usually commonly associated with 
Brenner tumor. Ovarian fibroma is usually accompanied by ascites 
and sometimes with right sided pleural effusion. Such a combination 
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of ovarian fibroma, right sided peural effusion and ascites is known as 
meigs syndrome.  
 
Metastastic (Secondary) carcinoma of Ovary:  
 Around 20% of ovarian cancers are secondary carcinoma with 
primary elsewhere in the body. The most common primary sites are 
Gastrointestinal tract especially pylorus, colon, gall bladder, pancreas, 
breast, uterus and cervix. There are two types of secondary carcinoma 
of the ovary. In the first type, the secondaries are deposited over the 
ovary either by direct spread within the peritoneal cavity or by 
lymphatic permeation. It is usually bilateral with bosselated 
appearance. This type is associated with ascites and peritoneal 
deposits. It is a peculiar to note that the ovarian secondaries are larger 
than secondary deposits.   
 The other type of secondary ovarian carcinoma is Krukenberg 
tumor. This   tumor is bilateral with smooth surface. The capsule is 
intact and ovary retains its shape. The histological picture shows the 
characteristic picture of signet ring cell. The Krukenberg tumor is 
larger than the primary tumor. The primary is most commonly from 
pylorus, colon and breast. The mode of spread is by retrograde   
lymphatic spread.  
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MATERIALS AND METHODS 
 
    This prospective study was performed in the Institute of 
Obstetrics and gynaecology, Madras Medical College, Egmore, 
Chennai. The study was conducted during the period 2010 to 2012. 
 
Study population : The study consisted of 200 patients who 
were admitted in our institute with adnexal masses.  
 
INCLUSION CRITERIA 
Patients above the age of 30 years admitted in our hospital both 
in premenopausal and postmenopausal age group with a diagnosis of 
an ovarian mass were included in the study. 
 
EXCLUSION CRITERIA 
Ovarian mass in the pregnant women were excluded because 
CA 125 levels will be elevated in pregnancy and hence may give a 
false positive result 
For the same reason, patient with endometriosis was also 
excluded from the study. 
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          Patients with previously diagnosed disease commonly 
associated with elevated CA 125 levels were excluded. 
 Patients on peritoneal dialysis which by constant peritoneal 
irritation cause an elevated CA 125 levels and are therefore exclude 
from the study. 
 
This study was performed after Institutional ethical committee 
approval. The objective of the study was explained in detail and 
written consent was obtained from the patients included in the study. 
 
Serum CA 125 and the ultrasound examination were performed 
at the time of preoperative laboratory assessment which was usually 
accomplished approximately within 1 week prior to surgery. Serum 
CA 125 was determined by radioimmunoassay. Ultrasound 
examination was performed using a 3.5-MHz abdominal convex 
transducer in patients with full bladder or 7.5-MHz vaginal probe in 
patients after empting the bladder. Ultrasound score was assigned for 
the following features 
1.  Multiloculations,  
2.  Presence of solid elements, 
3.  Bilaterality, 
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4.  Presence of ascites, or 
5.  Evidence of metastases. 
  An ultrasound score (U) of 1 was given if none or one of the 
features was found, and a score of 3 was given if two or more of these 
features were shown.   
 
Postmenopausal status was defined as more than one year of 
amenorrhea  or age older than 50 years for women who had undergone 
hysterectomy; they were scored as M=3. All other patients who did 
not meet these criteria were defined in a premenopausal status which 
scored M=1. The absolute values of serum CA-125 was entered in 
formula. 
 
 Ultrasonographic  examination of pelvic organs was performed, 
menopausal status and level of cancer antigen 125 (CA125) were 
assessed and finally RMI was calculated for all the patients. RMI was 
calculated using the formula: 
 
 
 
RMI SCORE = ultrasound score x menopausal score x CA 
                        125 level in U/ ml        
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After surgery, histopathological (HPE) findings of excised 
tumors were analysed in order to determine the final diagnosis. The 
histopathological diagnosis is considered as the gold standard for 
defining the outcomes. 
 
Finally, based on the standard formulas, sensitivity, specificity, 
positive predictive value and negative predictive value of the RMI was 
calculated, as RMI is an index which indicates malignancy with 
reference to the actual presence or absence of malignancy in the 
ovarian mass. 
 
SENSITIVITY: 
The sensitivity is defined as the percentage of patients with 
malignant ovarian mass having a positive test result. 
Sensitivity =   [(true positive / true positive + false negative) × 100] 
 
SPECIFICITY: 
 The specificity is defined as the percentage with benign ovarian 
mass showing negative results. 
Specificity = [(true negative / true negative + false positive) × 100] 
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POSITIVE PREDICTIVE VALUE  
The positive predictive value is defined as the percentage of 
patients with a positive test result having malignant ovarian mass. 
Positive predictive value = [(true positive / true positive + false 
positive) × 100]  
 
NEGATIVE PREDICTIVE VALUE 
 The negative predictive value is defined as the percentage of 
patients with a negative test result having benign ovarian mass. 
Negative predictive value = [(true negative / true negative + false 
negative) × 100] 
 
STATISTICAL ANALYSIS 
Data were analyzed using chi-square tests. Descriptive statistics 
were used for demographic data and summarized as mean with 
standard deviation  or frequency with percentage. Univariate  analyses 
to determine the association of each parameter were performed using 
Student’s  t  test. The independent association was then determined by 
logistic regression. 
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The predictive power of each factor and their combinations 
were assessed by the goodness of fit test at 1% significance and also 
by the receiver operating characteristic curve (ROC - Curve). The 
RMI was determined by combination of the three factors of CA125, 
Ultrasound  score, and menopausal status after the logistic model test 
for each factor. The ROC-Curves of CA 125, and RMI were 
constructed to determine the appropriate cut-off value for 
discriminating benign from borderline and malignant tumors. 
  
The diagnostic performances of each test were reported as 
sensitivity, specificity, positive predictive value, and negative 
predictive value with  95% confidence interval. 
 
 
 
 
 
 
 
 
 
 
 OBSERVATION & 
TABLE 1: 
HISTOPATHOLOGY
 
BENIGN 
 
 
MALIGNANT 
 
 
The study included 200 patients with ovarian
which 155 patients a
malignant comprising 22.5%.  
 
51 
77.50%
22.50%
HISTOPATHOLOGY
benign malignant
RESULTS 
 
 
NO. OF 
PATIENTS 
 
PERCENTAGE
155 77.5%
45 22.5%
 ma
re benign comprising 77.5% and 45 patients a
 
 
 
 
ss, out of 
re 
 0
10
20
30
40
50
60
70
80
90
100
30 -40
TABLE 2 : AGE DISTRIBUTION
AGE IN 
YEARS 
30-40 
41-50 38 (71.7%)
51-60 16 (48.5%)
>61 10 (71.4%)
 
In  the  age group of 51 to 60 years, 51.5% of cases are 
malignant whereas in 30 to 40 years of age, only 9% are malignant. 
The percentage of  
 
 
52 
41 -50 51 - 60
BENIGN MALIGNANT
 
BENIGN 
n  (%) 
MALIGNANT 
n (%) 
91  (91%) 9   (9%) 100 (50%)
 15 (28.3%) 53(26.5%)
 17 (51.5%) 33(16.5%)
 4(28.6%) 
malignant  tumor increases with increase in age.
> 61
TOTAL 
n (%) 
 
 
 
14 (7%) 
  
 0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
30 -
TABLE 3: 
HPE 
BENIGN 
MALIGNANT 
    
Among the 155 benign patients in our study, 58.7%
age group of 30 to 40 years, 24.5%
years, 10.3%  are in the age group of 51 
than 60 years.  
Among 45 malignant patients, 20%
33.3% belong to 41
are more than 60 years.  The possibility of malignancy increases with 
increasing age. 
53 
benign malignant
40 YRS 41 - 50 YRS 51 - 60 YRS >61 YRS
30 -40 41 -50 51 -60 
58.7% 24.5% 10.3% 
20% 33.3% 37.8% 
  are in the age group of 41 
– 60 years and 6.5%
 belong to 30 
-50 years, 37.8% belong to 51 – 60 years
>60 
6.5% 
8.9% 
  are in the 
– 50 
  are more 
-40 years, 
 and 8.9%  
 0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
REGULAR
TABLE 4 : MENSTRUAL HISTORY
MENSTRUAL PATTERN
REGULAR 
IRREGULAR 
POST MENOPAUSAL
 
In our study among the postmenopausal women, nearly half of 
the patients have malignant ovarian 
regular cycles and 31.7% with irregular cycles
 
 
 
54 
IRREGULAR POST 
MENOPAUSAL
BENIGN MALIGNANT
 
 
BENIGN 
n(%) 
MALIGNANT
n(%) 
100 (94.3%) 6 (5.7%) 
28 (68.3%) 13 (31.7%) 
 27 (50.9%) 26 (49.1%) 
tumor. 5.7% of the women with 
 have malignancy.
 
 
TOTAL 
n(%) 
 
106 (53%) 
41 (20.5%) 
53 (26.5%) 
 
 0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
BENIGN
REGULAR 
TABLE 5:  
HPE REGULAR
BENIGN 
MALIGNANT 
 
Among the women with malignant 
belongs to postmenopausal age group
benign tumor are in the postmenopausal status.  
 
 
 
 
 
55 
MALIGNANT
IRREGULAR POST MENOPAUSAL
 IRREGULAR POST MENOPAUSAL
64.5% 18.1% 17.4%
13.3% 28.9% 57.8%
tumor (n=45), 57.8% 
, whereas 17.4% of patients with 
 
 
P value 
 <0.001** 
 
 
 0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
BENIGN
TABLE 6 : PRE MENOPAUSAL AGE GROUP
HPE 
BENIGN 
MALIGNANT
 
Among the 147
patients with benign 
have  irregular cycle
regular cycles & 68.4%
 
 
 
 
56 
MALIGNANT
REGULAR IRREGULAR
 
REGULAR IRREGULAR
78.15% 21.9% 
 31.6% 68.4% 
 patients  in premenopausal age group, 78.1% of 
tumors  have regular cycle whereas the
s. 31.6% of patients with malignant 
  have  irregular cycles. 
 
 remaining 
tumors have 
 0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
TABLE 7 : PARITY DISTRIBUTION
PARITY INDEX 
NULLIPAROUS 
MULTIPAROUS 
 
In our study,
multiparous women. 51.9% has
nulliparous women have
women, 81.5% have
 
 
57 
NULLIPAROUS MULTIPAROUS
BENIGN MALIGNANT
 
BENIGN 
n (%) 
MALIGNANT 
n (%) 
TOTAL
n (%) 
14 
(51.9%) 
13         
(48.1%) 
27    
(13.5%)
141 
(81.5%) 
32            
(18.5%) 
173  
(86.5%)
 27 patients are nulliparous and 173 patients are 
 benign tumor and 48.1% of 
 malignant tumor. Among the multiparous 
 benign tumor and 18.5% have malignant
 P value 
 
<0.001** 
 
 
 tumor. 
 9%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
TABLE 8 :  PARITY DI
HPE 
BENIGN 
MALIGNANT 
 
Among  the  
and  91%  are multiparous
tumors, 28.9%  are nulliparous
 
 
 
 
 
 
58 
28.90%
91%
71%
BENIGN MALIGNANT
NULLIPAROUS MULTIPAROUS
STRIBUTION  
NULLIPAROUS MULTIPAROUS
9% 91%
28.9% 71.1%
patients  with benign  tumors,  9%  are nulliparous 
  and  among the patients with malignant 
  and  71.1%  are  multiparous.
 
 
 
 
 87.10%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
100.00%
PREMENOPAUSAL
TABLE 9 : MENOPAUSAL STATUS
MENOPAUSAL 
STATUS 
PREMENOPAUSAL
POSTMENOPAUSAL
 
  In our study,
53 patients are in post
menopausal patients,
87.1%  and 19  patients
Among 53 patients in postmenopausal age group,
have benign  tumor
malignant tumor  accounting
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50.90%
12.90%
49.10%
POSTMENOPAUSAL
BENIGN MALIGNANT
 
BENIGN 
n (%) 
MALIGNANT 
n (%) 
TOTAL
n (%)
 
128 
(87.1%) 
19        
(12.9%) 
147 
(73.5%)
 
27 
(50.9%) 
26        
(49.1%) 
53 
(26.5%)
 147 patients are in premenopausal age group and 
menopausal age group.  Among 147 pre 
 128 patients have benign tumor accounting
  have malignant tumor accounting
s  accounting  for  50.9%  and  26 patients
  for 49.1%. 
 
 
P value 
 
<0.001% 
 
  for  
  for 12.9%. 
 27 patients 
  have 
 0.00%
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40.00%
60.00%
80.00%
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TABLE 10 :  
HPE 
BENIGN 
MALIGNANT 
 
Among 155 benign 
menopausal age group and 17.4%
Among 45 patients with malignant 
menopausal age group and 57.8% a
The sensitivity of the menopausal score in differentiating benign and 
malignant tumor is 57.8%, the specificity is 82.6%, the 
predictive value is 49.1% and 
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BENIGN
MALIGNANT
82.60%
17.40%
42.20% 57.80%
PREMENOPAUSAL POSTMENOPAUSAL
PREMENOPAUSAL POSTMENOPAUSAL
82.6% 42.2%
17.4% 57.8%
tumors, 82.6% of patients are in pre 
  are in post menopausal age group. 
tumors, 42.2% a
re in postmenopausal age group.
negative predictive value is 87.1%.
 
 
 
re in pre 
  
positive 
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TABLE 11 : ULTRASOUND SCORE
ULTRASOUND 
SCORE 
1 
3 
 
115 patients have
or more parameters in ultrasoun
patients (90.4%) have
malignant tumor.  
presence of 2 or more parameter
with ultrasound score of 3
and 34 patients have 
 
61 
USG 1
USG  3
90.40%
60%
9.60%
40%
BENIGN MALIGNANT
 
BENIGN 
n (%) 
MALIGNANT 
n (%) 
TOTAL 
n (%) 
104 
(90.4%) 
11          
(9.6%) 
115 
(57.5%) 
51     
(60%) 
34           
(40%) 
85 
(42.5%) 
 ultrasound score of 1, that is presence of one 
d scan. Among 115 patients, 104
 benign lesions and 11 patients (9.6%) have
85 patients have ultrasound score of 3
s of ultrasound criteria. 
 have benign lesions accounting for 60% 
malignant lesions accounting for 40%.
P value 
<0.001** 
 
 
, indicating 
 51 patients 
 
 0.00%
20.00%
40.00%
60.00%
80.00%
TABLE 12 : 
ULTRASOUND 
SCORE
BENIGN
MALIGNANT
      
    On analysis, among benign 
1 and 32.9%  have
24.4% have ultrasound score of 1,
of 3.   The performance
analysed with sensitivity of 
predictive  value  of
is statistically highly significant with P value <0.01 using 
square test. 
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U=1
U=3
BENIGN
MALIGNANT
67.10%
24.40%
32.90%
75.60%
U=1 U=3
 
U=1 U=3 
 67.1% 32.9% 
 24.4% 75.6% 
tumors  67.1% have  ultrasound score of 
  ultrasound score of 3. Among malignant 
 and 75.6%  have ultrasound score 
  status of ultrasound  score 
 75.6%,  specificity  of  67.1%, 
  40%,  negative predictive value  of  
tumor, 
 has  been  
 positive  
90.4%  and it 
 pearson chi 
 0%
20%
40%
60%
80%
100%
CA 125 <35 U/ML
TABLE 13 : CA 125 
CA 125 BENIGN
n (%)
< 35 U/ml 94 (94%)
>  35 U/ml 61 (61%)
 
  The CA 125 value i
normal range is  0-35 
U/ml,  100 patients have
more than 35 U/ml.
benign lesions and 6% have
CA 125>35 U/ml, 
lesions. 
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BENIGN
MALIGNANT
CA 125 >35 U/ML
94%
61%
6%
39%
BENIGN MALIGNANT
 
 
 
MALIGNANT 
n (%) 
TOTAL 
n (%) 
 6 (6%) 100 (50%) 
 39 (39%) 100 (50%) 
s analysed with a cut off value of 35 
U/ml.  In our study,  CA 125 with a cut off of 35 
 less than 35 IU/ml and 100 patients have
  94% of  patients with CA 125 < 35 
 malignant lesions.  Among patients with 
61% have benign lesions and 39% have
P value 
<0.001** 
U/ml. The  
 
U/ml have 
 malignant 
 0.00%
20.00%
40.00%
60.00%
80.00%
100.00%
TABLE 14 :  
HPE 
BENIGN
MALIGNANT
 
Among the patients with benign 
<35 U/ml and 39.4% have
with malignant tumor
CA 125 >35 U/ml.
benign  and  malignant  
positive predictive value i
94.0%. 
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CA 125 <35U/ml
CA 125 >35U/ml
BENIGN
MALIGNANT
60.60%
13.30%
39.40%
86.70%
CA 125 <35U/ml CA 125 >35U/ml
CA 125 
< 35 U/ml > 35 U/ml 
 60.6% 39.4% 
 13.3% 86.7% 
tumor, 60.6%  have  CA 125 
 CA 125 > 35 U/ml. whereas 
,13.3% have  CA 125 < 35 U/ml and 86.7% have
  The sensitivity of CA 125 in discriminating
tumor is 86.7%, the specificity i
s 39% and negative predictive value i
 the patients 
 
  
s 60.6%,  the 
s 
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TABLE 15 : DISTRIBUTION OF RMI AT CUT OFF VALUE 100
RMI BENIGN
n (%)
<100 123 (97.6%)
>100 32 (43.2%)
 
RMI AT CUT OFF VALUE OF 100
SENSITIVITY – 93.3%
SPECIFICITY – 79.4%
POSITIVE PREDICTIVE VALUE 
NEGATIVE PREDICTIVE VALUE 
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Benign
Malignant
RMI >100
97.60%
43.20%
2.40%
56.80%
Benign Malignant
 
 
MALIGNANT 
n (%) 
TOTAL 
n (%) 
 3 (2.4%) 126 (63%) 
 42 (56.8%) 74 (37%) 
 
 
 
– 56.8% 
– 97.6% 
 
P value 
<0.001** 
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The risk of malignancy index  based  on  USG  score, CA -125  
and menopausal status was calculated preoperatively. With the cut off 
value of 100, 126  patients are below 100  and 74 patients are above 
100.  97.6% of  patient with RMI <100  have benign tumor and 56.8% 
of  patients with RMI >100 have malignant tumor.  79.4% of patients 
with benign tumor have RMI <100 and 93.3% of patients with  
malignant  tumor have  RMI > 100.  The sensitivity of  RMI with cut 
off  point  of  100  is 93.3%, specificity is 79.4%, positive predictive 
value is 56.8% and negative predictive value is 97.6%. 
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TABLE 16 : DISTRIBUTION OF 
RMI BENIGN
n (%)
<150 136 (93.8%)
>150 90 (34.5%)
 
RMI  AT CUT OFF VALUE OF 150
SENSITIVITY – 80%
SPECIFICITY – 87%
POSITIVE PREDICTIVE VALUE 
NEGATIVE PREDICTIVE VALUE 
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34.50%
6.20%
65.50%
RMI <150 RMI >150
BENIGN MALIGNANT
RMI AT CUT OFF VALUE
OF150 
 
 
MALIGNANT 
n (%) 
TOTAL 
n (%) 
 9 (6.2%) 145 (72.5%) 
 36 (65.5%) 55 (27.5%) 
 
 
 
– 65.5% 
– 93.8% 
 
P value 
<0.001** 
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With the cut off value of  RMI at 150, 145 patients have value 
below 150 and 55 patients have value above 150.  Patients with RMI 
<150, 93.8% have benign lesions and 6.2% have malignant lesions 
.Those with RMI > 150, 34.5% have benign lesions and 65.5% have 
malignant lesions.  87.7% of patients with benign tumors  have RMI < 
150 and 80% of patients with  malignant tumors  have RMI  >  150.  
With the cut off value of 150 , sensitivity,  specificity , positive 
predictive value and negative predictive value are S 80%, 87.7%, 
65.5% and 93.8% respectively. 
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TABLE 17 : DISTRIBUTION OF RMI AT CUT OFF VALUE OF
RMI BENIGN
n (%)
< 200 146 (94.2%)
> 200 9 (20%)
 
RMI AT CUT OFF VALUE OF 200
SENSITIVITY – 80%
SPECIFICITY – 94.2%
POSITIVE PREDICTIVE VALUE 
NEGATIVE PREDICTIVE VALUE 
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20%
5.80%
RMI< 200 RMI> 200
BENIGN MALIGNANT
 
 
MALIGNANT 
n (%) 
TOTAL 
n (%) 
 9 (5.8%) 155 (77.5%) 
 36 (80%) 45 (22.5%) 
 
 
 
– 80% 
– 94.2% 
80%
 200 
P value 
<0.001** 
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155 patients have RMI value <200 and 45 patients have RMI > 
200.   94.2% and 5.8% of patients with RMI < 200 have benign and 
malignant tumor respectively .Those with RMI >200, 20% have 
benign lesions and 80% have malignant tumors.  94.2% of the patients 
with benign tumor have RMI < 200 and 5.8% have RMI >200. 20% of 
patients with malignancy have RMI <200 and 80% have RMI >200.  
The sensitivity of RMI with cut off value 200 is 80% ,specificity is 
94.2%, positive predictive value is 80%, negative predictive value is 
94.2%.According to  pearson chi-square test and Fischer exact test the 
P value is <0.01, which is statistically significant . 
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TABLE 18 : DISTRIBUTION OF RMI AT CUT OFF VALUE OF
RMI 
 
BENIGN
n (%) 
<250 150 ( 92%)
>250 5 (13.5%)
 
RMI  AT CUT OFF VALUE OF 250
SENSITIVITY – 71.1%
SPECIFICITY – 96.8%
POSITIVE  PREDICTIVE VALUE 
NEGATIVE PREDICTIVE VALUE 
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13.50%
8%
86.50%
RMI <250 RMI >250
BENIGN MALIGNANT
 
 
MALIGNANT 
n (%) 
 
TOTAL 
n (%) 
 13 (8%) 163 (81.5%) 
 32 (86.5%) 37 (18.5%) 
 
 
 
– 86.5% 
– 92% 
 250 
P value 
<0.001** 
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If the RMI has the cut off value of 250 , 163 patients have RMI 
< 250 and 37 patients have  RMI > 250.    92 % of patients with RMI 
< 250 have benign lesion and 8% have malignant lesions.13.5% of 
patients with RMI > 250 have benign lesions and 86.5% of patients 
have malignant  lesions .  Among patients with benign lesion  96.8% 
have RMI <200 and 3.2%  have RMI >200.  In  patients with 
malignant tumors  28.9% have  RMI < 200, 71.1% have RMI >200. 
           
The sensitivity of the RMI with cut off value of 250 in 
differentiating benign and malignant tumor is 71.1%, specificity is 
96.8%, positive predictive value is 86.5% and negative predictive 
value is 92% . 
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TABLE 19 : COMPARISION OF RMI IN DIFFERENT CUT OFF
  VALUES
 
RMI 
CUT 
OFF 
VALUE 
SENSITIVITY
100 93.3%
150 80%
200 80%
250 71.1%
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RMI 150 RMI 200
SENSITIVITY SPECIFICITY PPV NPV
  
 SPECIFICITY 
POSITIVE
PREDICTIVE 
VALUE 
 79.4% 56.8% 
 87.7% 65.5% 
 94.2% 80% 
 96.8% 86.5% 
RMI 250
 
 NEGATIVE 
PREDICTIVE 
VALUE 
97.6% 
93.8% 
94.2% 
92% 
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The sensitivity of the RMI in discriminating benign and 
malignant ovarian tumor is high with the cut off value of 100. The 
sensitivity decreases as the cut off value of RMI is increased. The 
specificity of  RMI  is high with the cut off value of 250. As 
specificity is (1- sensitivity), it increases with increase in the cut off 
value of RMI. Likewise the positive predictive value increases with 
increase in the cut off value of RMI. The positive predictive value is 
high at the cut off value of 250.  The negative predictive value 
decreases with increase in the cut off value of RMI. The negative 
predictive value is high at the cut off value of 100. 
 The optimal sensitivity, specificity, positive predictive value 
and negative predictive value for RMI is at the cut off value of 
200.The cut off value of RMI at  200 is highly statistically significant, 
associated with the gold standard (HPE) i.e. malignant or benign. 
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TABLE 21: COMPARISION OF SENSITIVITY, SPECIFICITY,  
  PPV AND NPV OF VARIOUS PARAMETERS 
 
 
SENSITIVITY SPECIFICITY 
POSITIVE 
PREDICTIVE 
VALUE 
NEGATIVE 
PREDICTIVE 
VALUE 
 
PARITY 
 
28.9% 91% 48.1% 81.5% 
IRREGULAR 
MENTURAL 
CYCLES 
68.4% 78.1% 31.7% 94.3% 
MENOPAUSAL 
SCORE 57.8% 82.6% 49.1% 87.1% 
 
USG SCORE 
 
75.6% 67.1% 40% 90.4% 
 
CA 125 
 
86.7% 60.6% 39% 94% 
 
RMI 
 
80% 94.2% 80% 94.2% 
 
The sensitivity of parity as a diagnostic  indicator is low  28.9%, 
the specificity is high  91%, the positive predictive value is 48.1% and 
negative predictive value is 81.5% . Menstrual disturbances as a 
parameter has the sensitivity 68.4%, specificity 78.1%, positive 
predictive value   31.7% and negative predictive value 94.3%. 
The diagnostic performance of sensitivity of menopausal score 
is 57.8%, specificity is 82.6%, positive predictive value is 49.1% and 
negative predictive value is 87.1%. Thus menopausal score has high 
specificity and negative predictive value.  
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 The sensitivity of ultrasound score as diagnostic modality in 
differentiating benign and malignant tumor is 75.6%, specificity is 
67.1%, positive predictive value is 40% and negative predictive value 
is 90.4%. The sensitivity and negative predictive value are high for 
ultrasound score. 
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The sensitivity of CA 125 with a cut off value of 35 U/ml is 
86.7%, specificity is 60.6%, positive predictive value is 39% and 
negative predictive value is 94%. CA 125 has high sensitivity and 
negative predictive value. 
 The diagnostic performance of sensitivity, specificity, positive 
predictive value and negative predictive value of RMI at cut off  value 
of  200  are 80%, 94.2%, 80% and 94.2% respectively. We found that 
RMI has better performance than CA 125, ultrasound score and 
menopausal score. 
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HISTOPATHOLOGY 
 
BENIGN TUMORS 
S.NO HISTOPATHOLOGY 
NO. OF 
PATIENTS 
% OF 
BENIGN 
TUMORS 
% OF 
TOTAL 
1 FOLLICULAR CYST 1 0.6 0.5 
2 CHYLOLYMPHATIC CYST 1 0.6 0.6 
3 CORPUS LUTEAL CYST 1 0.6 0.5 
4 SEROUS CYSTADENOMA 77 49.7 38.5 
5 
PAPILLARY SEROUS 
CYSTADENOMA 
4 2.6 2 
6 
MUCNOUS 
CYSTADENOMA 
25 16.1 12.5 
7 DERMOID 34 21.9 17 
8 SIMPLE SEROUS CYST 6 3.9 3 
9 STRUMA OVARII 2 1.3 1 
10 LUETINISED THECOMA 1 0.6 0.5 
11 FIBRO THECOMA 3 1.9 1.5 
 
 
 2.6
16.1
21.9
3.9 1.3
0.6
In the study, serous cyst
tumor in our populat
49.7%  of  benign 
dermoid  constituting 17% of total cases and 21.9% of benign
The next common benign 
accounts for 12.5% of total cases and 16.1% of benign cases.
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0.6
0.6
0.6
49.7
1.9
Series 1
FOLLICULAR CYST
CHYLOLYMPHATIC CYST
CORPUS LUTEAL CYST
SEROUS CYSTADENOMA
PAPILLARY SEROUS 
CYSTADENOMA
MUCNOUS CYSTADENOMA
DERMOID
adenoma is the most common benign 
ion. The incidence is 38.5% and  
tumors. The second common benign
tumor is mucinous cystadenoma which 
accounts for 
  tumor  is 
  tumors. 
 
80 
 
MALIGNANT TUMORS 
S.NO HISTOPATHOLOGY 
N0.OF 
PATIENTS 
% OF 
MALIGNANT 
% OF 
TOTAL 
1 
PAPILLARY SEROUS 
CYSTADENO 
CARCINOMA 
15 33.3 7.5 
2 
SEROUS 
CYSTADENO 
CARCINOMA 
7 15.6 3.5 
3 
ATYPICAL 
PROLIFERATIVE 
SEROMUCINOUS 
TUMOR 
4 8.9 2 
4 
MUCINOUS 
CYSTADENO 
CARCINOMA 
9 20 4.5 
5 
ENDOMETROID 
ADENOCARCINOMA 
7 15.6 3.5 
6 
GRANULOSA CELL 
TUMOR 
2 4.4 1 
7 
MALIGNANT 
BRENNER TUMOR 
1 2.2 0.5 
 
   
 20
15.6
4.4
In our study, the most common malignant 
cystadenocarcinoma comprising 33.3% of patients with malignant 
cancer. It accounts for 7.5% of total patients. The second common 
malignant tumor is mucinous cystadenocarcinoma accounting for 20% 
of benign cases and 4.5% of total cases. The next
tumors are serous cystadenocarcinoma, endometrioid carcinoma each 
accounting for 15.6% of malignant patients and 3.5% of total patients. 
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33.3
15.68.9
2.2
Series 1
PAPILLARY SEROUS 
CYSTADENOCARCINOMA
SEROUS 
CYSTADENOCARCINOMA
ATYPICAL PROLIFERATIVE 
SEROMUCINOUS TUMOUR
MUCINOUS 
CYSTADENOCARCINOMA
ENDOMETROID 
ADENOCARCINOMA
GRANULOSA CELL TUMOUR
MALIGNANT BRENNER 
TUMOUR
tumor
 common malignant 
 is papillary 
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DISTRIBUTION OF AGE, MENOPAUSAL STATUS, 
ULTRASOUND SCORE, CA 125 LEVELS AND RMI IN 
PATIENTS WITH BENIGN OVARIAN MASS (n=155) AND 
MALIGNANT OVARIAN MASS (n=45) 
CRITERIA BENIGN MALIGNANT P VALUE 
 
AGE (MEAN +/_ SD) 
 
40.74 +/_ 10.36 
 
49.47 +/_ 9.96 
 
<  0.001** 
MENOPAUSAL  
STATUS 
PREMENOPAUSAL 
 
 
POSTMENOPAUSAL 
 
 
128 (87.1%) 
 
19 (12.9%)  
< 0.001** 
27 (50.9%) 26 (49.1%) 
ULTRASOUND SCORE 
 
1 
 
3 
 
 
104 (90.4%) 
 
 
11 (9.6%)  
< 0.001** 
51 (60%) 34 (40%) 
SERUM CA 125 
(MEAN+/_SD) 
34.20 +/_26.22 212.67 +/_222.24 < 0.001** 
RMI (MEAN +/_SD) 81.56+/-133.3 1158.45 +/_1752.13 < 0.001** 
 
The statistical analysis of multiple variables showed that CA 
125, ultrasound score and RMI are the independent predictors of 
malignancy.  
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RECEIVER OPERATING CHARACTERISTIC CURVES 
 
 
 
 
Test Result Variable(s): RMI  
Area Std. Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% 
Confidence Interval 
.929 
.022 .000 .885 .973 
 
a. Under the nonparametric assumption 
b. Null hypothesis : True area = 0.5 
 
 
 
Test Result Variable(s): CA 125  
Area 
Std. 
Error(a) 
Asymptotic 
Sig.(b) 
Asymptotic 95% 
Confidence Interval 
.847 .039 .000 .771 .924 
a. Under the nonparametric assumption 
b. Null hypothesis : True area = 0.5 
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DISCUSSION 
In our study, the peak incidence of the malignant ovarian tumor 
was 51-60 years of age during which 51.6% of ovarian tumors were 
malignant. The study shows that among those less than40 years of age 
group, most of the neoplasms were benign and as age increases the 
risk of malignancy increases. 
 
Various case control studies have shown that pregnancy reduces 
the risk of ovarian cancer. One pregnancy reduces the risk of ovarian 
cancer by as much as one third and with subsequent  preganancies  the 
risk lowers further. Infertility has an  increased risk of ovarian 
malignancy around 2 fold. In our study the ovarian mass among 
nulliparous women had more incidence of malignancy when compared 
to multiparous women. The study showed among nulliparous women 
48.1% had malignant tumors compared to 18.5% in multiparous 
women.  
 
On analysing the menstrual history, nearly half of the 
postmenopausal women had malignant ovarian tumor. Among 
menstruating women there was a high chance of malignancy in those 
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with irregular cycles when compared to patients with regular cycle. 
The most common irregularity noted was prolonged cycles. 
 
The study showed that the patients who had malignant ovarian 
neoplasm, most of them were in the postmenopausal status. 49.1% of 
postmenopausal women had malignancy when compared to 12.9% in  
premenopausal women. Thus in postmenopausal women the malignant 
neoplasms are more common.  
 
Sonographic evaluation of the structure of an ovarian mass in 
predicting the risk of malignancy have been reported. Many 
investigators have developed the objective Ultrasound score according 
to various ovarian morphologies to minimize the examiners 
descriptive interpretation which may be varied and not reproducible. 
Many scoring systems based on various ultrasonographic 
morphologies have been made for this purpose. These scoring 
morphologies are tumor volume, number of locularities, wall 
thickness, inner wall structure, septal structure, and shadowing or 
echogenicity  or solid area . At different cut-off levels of Ultrasound  
scores as an indicator for discrimination of benign from malignant 
tumors, the sensitivity, specificity, positive predictive value (PPV) and 
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a negative predictive value (NPV) from these studies ranged from 74-
88%, 40-65%, 28-36%, and 90-95%, respectively. Ferrazzi et al [45]., 
in1997, developed the new multicenter scoring system in 
determination of malignancy status of ovarian tumors based on the 
ultrasound  morphology of the ovarian cyst wall, septae, vegetations, 
and echogenicity. The new scoring system yielded better result than 
the previous scoring systems reported in the other studies with the 
accuracy, sensitivity, specificity, positive predictive value and 
negative predictive value of 72%, 87%, 67%, 41% and 95%, 
respectively. 
 
For  ultrasonographic  technique in diagnosing ovarian cancer 
the sensitivity was 62% and specificity was 73%  as shown in various 
study including  Morgante et al [23] 1999,  Leelahakorn et al [47] 2005. 
 
In our study, the sensitivity of ultrasonographic score was 
75.6% and specificity was 67.1%, the positive predictive value was 
40% and negative predictive value was 90.4%. 
 
 The study showed that ultrasonogram of complex ovarian mass 
has more malignant potential.  
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All though the value of CA 125 as a screening test for ovarian 
cancer is yet unsettled, its role for a differential diagnosis of ovarian 
mass is clearly established. CA125 a tumor marker for ovarian cancer 
is not specific. With a cut off value of 35 U/ml,  
True positive – 39% 
True negative – 94% 
False positive – 61% 
False negative – 6% 
 
Among the six false negative cases,  2 cases were granulosa cell 
tumor. 3 were mucinous cystadenocarcinoma  and one was borderline  
papillary serous cystadenocarcinoma. 
 
Among 61% false positive cases, 81.96% (50 cases) were 
serous cystadenoma, less than 10% (6 cases) were mucinous 
cystadenoma.  
 
CA 125 level has overall  range of   6.7 – 832.64.The  high 
values  of CA 125 is found most commonly with papillary serous 
cystadenocarcinoma and endometrioid  adenocarcinoma.  
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Benjapi bal et al [44], 2007 showed that CA 125 at the cut off 
level of 35 U/ml had the sensitivity of  83.1% and specificity of 
39.3%. In 2010, Rachmasari putri et al study showed that CA 125 
level at a cut off value of 35 U/ml had a sensitivity of 81.43% and 
specificity of 60%, positive predictive value of 87.69% and negative 
predictive value of 48%. 
 
In our study, the sensitivity was 86.7% and the specificity was 
60.6% the positive predictive value and the negative predictive value 
were 39% and 94% respectively. Our study showed that CA 125 has 
high sensitivity and high negative predictive value. The specificity 
was poor in predicting malignancy. 
 
      RMI was calculated using the formula for each patient included in 
the study (n=200). Out of 200 patients, the RMI with cut off value of 
200,155 patients  had benign tumor and  45 patients  had malignant 
tumor. 
True positive - 36 cases 
True negative - 146 cases 
False positive - 9 cases 
False negative - 9 cases 
Total   - 200 cases 
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9 patients with RMI less than 200 had malignant ovarian cancer 
constituting   false negative (5.8%). Out of 9 patients, 2 patients had 
granulosa cell tumor and 7 patients had mucinous 
cystadenocarcinoma. 
Among the 45 patients with RMI >200, 9 patients (20%) had 
benign tumors constituting the false positive cases. Out of 9 patients, 8 
patients had serous cystadenoma and 1 patient had mucinous 
cystadenoma. 
Thus serous cystadenoma was the most common cause of false 
positivity  and  mucinous cystadenocarcinoma was the most common 
cause for false negativity. 
The false positive  rates  are important when a particular test has 
to be used in low risk populations diagnosed with ovarian mass during 
screening of  ovarian  abnormalities. 
        Among the benign tumors, the RMI had a range from  6.7 to 
865.35.The mean RMI was 81.55 with SD 133.31. Among the 
malignant tumors the range is from 28.92 to 7493.76. The average 
RMI was 1158.44 with SD 1752.13. This was statistically significant 
with P value <0.001**. 
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 In our study, the performance of sensitivity, specificity, positive 
predictive value and negative predictive value of RMI at various cut 
off levels of 100,150, 200, 250, were analysed. At a cut off level of 
100, the RMI had highest sensitivity (93.3%) and negative predictive 
value (97.6%).The specificity (79.4%) and positive predictive value 
(56.8%) were low. As the cut off levels are increased, the sensitivity 
decreases and specificity increases. RMI at cut off value of 250, has 
the highest specificity (96.8%) and positive predictive value (86.5%). 
The sensitivity was low 71.1%. Multiple studies have shown that the 
best cut off value of RMI is 200. In our study, the performance of RMI 
at 200 is statistically significant as shown by the sensitivity 80%, 
specificity 94.2%, positive predictive value 80% and negative 
predictive value 94.2%. 
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COMPARISON OF THE VARIOUS PREVIOUS STUDIES WITH 
THE PRESENT STUDY 
STUDY YEAR 
NO. 
OF 
PTS 
SENSITI-
VITY 
SPECIFI-
CITY PPV NPV 
JACOB ET AL 1990 143 85.4% 96.6% - - 
DAVIES ET AL 1993 124 87% 89% - - 
TINGULSTAD 
ET AL 1996 173 71% 96% 89% 88% 
TINGULSTAD 1999 365 71% 92% 69% 92% 
MORGANTE ET 
AL 1999 124 58% 95% 78% 87% 
MANJUNATH 
ET AL 2000 152 73% 91% 93% 67% 
MA ET AL 2003 140 87.3% 84.4% 82.1% 89% 
TORRES ET AL 2003 158 73% 86% - - 
ANDERSON ET 
AL 2003 180 70.6% 87.7% 66.1% 89.8% 
OBEIDAT ET AL 2004 100 90% 89% 96% 78% 
LEELAHAKORN 
ET AL 2005 175 88.6% 90.7% 70.5% 97% 
ULUSOY ET AL 2007 296 71.7% 80.5% 67.3% 83.6% 
VAN DEN 
AKKER ET AL 2010 548 81% 85% 48% 96% 
BOUZARI ET 
AL 2011 182 91.3% 88% 52% 98.58% 
MONIRATH 
HAV ET AL 2011 151 89.5% 94.7% 71% 98% 
ERHAN 
AKTURK ET AL 2012 100 75% 87% 57% 93% 
PRESENT 
STUDY 2012 200 80% 96.8% 86.5% 92% 
 
VALUES FOR RMI 200 
 0.00%
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                                     SUMMARY 
 
 
 200 women with ovarian mass above 30 years of age were 
selected for the study.  Patients with pregnancy and 
endometriosis are excluded. 
 50%  patients were in the age group of 30 – 40 years,26.5% in 
41 – 50 years, 17.5 %  in 51 – 60 years and 7% in  >60 years. 
 General and gynaecological examination was done for all cases. 
 Ultrasound pelvis was done for all patients and the presence of 
bilateral ovarian mass, multiloculated tumor, presence of solid 
areas, ascites and extraovarian metastasis were noted. An 
ultrasound score (U) of 1 was given if none or one of the 
features was found, and a score of 3 was given if two or more of 
these features were shown.       
 Serum CA 125 level was measured preoperatively. 
 Postmenopausal status was defined as more than one year of 
amenorrhea or age older than 50 years for women who had 
undergone hysterectomy; they were scored as M=3. All other 
patients who did not meet these criteria were defined in a 
premenopausal status which scored M=1. 
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 Risk of malignancy index was calculated based on RMI 3 
(modified by Tingulstad [20] in 1999). 
 Laparotomy was done for all cases and the specimen was sent 
for histopathological examination which is the gold standard. 
 77.5% of the tumor was benign and 22.5% was malignant. 
 Prediction of malignancy by CA 125, ultrasound and RMI was 
compared and analysed . 
 The   optimal sensitivity, specificity, positive predictive value 
and negative predictive value for RMI was at the cut off value 
of 200. 
 The  diagnostic  performance  of  sensitivity , specificity, 
positive predictive value and negative predictive value of  RMI 
at cut off  value of  200  were 80%, 94.2%, 80% and 94.2% 
respectively. 
 Though CA 125 was highly sensitive (sensitivity was 86.7% ), 
specificity and PPV were poor. 
 The study showed that RMI has the better performance than CA 
125, ultrasound score and menopausal score in the prediction of 
malignancy. 
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CONCLUSION 
Risk of malignancy index is a reliable method for differentiating 
benign and malignant ovarian mass preoperatively. 
Risk of malignancy index is a multimodal approach that is 
simple and easily applicable in preoperative evaluation of patients 
with ovarian tumor. 
Risk of malignancy index is a better diagnostic scoring index in 
discriminating benign and malignant tumor when compared to 
individual test of ultrasonogram or CA 125 level. 
The optimal cut off point that best distinguishes benign from 
malignant ovarian mass for RMI is 200 in the present study. 
RMI is the most useful diagnostic index in proper selection of 
patients who may require referral to tertiary care centres. 
Since the specificity of Risk of malignancy index is high, there 
is a potential role for this index in selection of cases for conservative 
management or minimal invasive surgery of benign cases like 
ultrasound guided aspiration or laparoscopic excision of the cysts. 
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PRESENTING ILLNESS : MASS     
     DURATION 
     PAIN ABDOMEN 
     ABD DISTENSION 
MENSTRUAL HISTORY : 
MENOPAUSE  YES  NO 
MARRIED   YES  NO NO.OF YEARS 
OBSTETRIC HISTORY :  NULLIPAROUS 
PAROUS 
      NOC 
      LCB 
      OVULATION INDUCTION 
 
CONTRACEPTION :  YES  NO 
     OCP 
     ST 
     OTHERS 
 
  
PAST MEDICAL HISTORY :  DM 
      HT 
      IHD 
      NA 
SURGICAL HISTORY :   YES  NO 
FAMILY HISTORY :   OVARIAN MALIGNANCY 
      ENDOMETRIAL CA 
      BREAST CA. 
GENERAL EXAMINATION   :                                                             
      HEIGHT: 
     WEIGHT: 
     BMI:  
O/E     ANAEMIA 
     PEDAL EDEMA 
     LYMPH NODES 
     BREAST 
     THYROID 
VITAL SIGNS   PR    BP 
P/A     MASS 
     ASCITES 
     OTHERS 
P/S 
P/V 
  
USG ABDOMEN & PELVIS 
S NO USG FEATURES PRESENT/ABSENT 
1 MULTI SEPTATIONS  
2 SOLID COMPONENTS  
3 BILATERALITY  
4 ASCITES  
5 METASTATIC LESIONS  
 
ULTRASOUND SCORE  : 
CA 125 VALUE    : 
MENOPAUSAL SCORE  :  
RISK OF MALIGNANCY INDEX : 
LAPAROTOMY FINDINGS   
HPE 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
CONSENT FORM 
STUDY TITLE    :   STUDY OF RISK OF MALIGNANCY INDEX 
IN THE PREOPERATIVE  EVALUATION OF PATIENTS WITH 
OVARIAN TUMOR 
STUDY CENTRE :      Institute of Obstetrics and Gynaecology, 
       Egmore,Chennai  
 
Participant Name:                             Age:            Sex:          I.D.No.: 
I confirm that I have understood the purpose of the above study. I have 
the opportunity to ask the questions and all my questions and doubts 
have been answered to my satisfaction.  
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving any reason.  
I understand that the investigator, regularity authorities and the ethics 
committee will not need my permission to look at my health records 
both in respect to the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the study. I 
understand that my identity will not be revealed in any information 
released to third parties of published, unless as required under the law. 
I agree not to restrict the use of any results that arise from the study. 
I hereby consent to participate in this study titled “STUDY OF RISK 
OF MALIGNANCY INDEX IN THE PREOPERATIVE  
EVALUATION OF PATIENTS WITH OVARIAN TUMOR” 
Signature of Investigator:   
Study Investigators Name: 
Signature/thumb impression of patient 
Date  :                                Thanking you,  
Place  :                                            Yours faithfully, 
  
MASTER CHART 
S. 
No NAME AGE IP No COMPLAINTS 
MENSTRUAL 
HISTORY PARITY 
MENO 
SCORE 
USG  
SCORE 
CA 125 VALUE 
U/ml RMI HPE 
1 SUMATHY 30 3487 PAIN ABD REG P1L1 1 1 27.4 27.4 SC 
2 SARAL 38 4958 PAIN ABD IRREG P3L2/ST 1 1 18.9 18.9 SC 
3 DESAMAL 31 3721 PAIN ABD REG P2L2 1 3 17.8 53.4 PSC 
4 PAVUN 55 4399 
PAIN 
ABD,DISTENTION MNP-5 NG 3 1 51.73 155.19 MC 
5 SUNDARI 50 2830 PAIN ABD REG P5L2 1 1 18.43 18.43 
LUETINISED 
THECOMA 
6 SHAMEMA 32 5317 PAIN ABD REG P2L2/ST 1 1 53.75 53.75 SC 
7 KALAVATHY 43 32934 
PAIN ABD, 
DISTENTION IRREG P2L2A1 1 1 15.38 15.38 MC 
8 PACHAIAMMA 50 5600 PAIN ABD MNP-2 P4L3/ST 3 1 23.6 70.8 SC 
9 ANJALI 30 5059 PAIN ABD REG NG 1 3 13.01 39.03 DERMOID 
10 KARPAGAM 33 5920 PAIN ABDOMEN IRREG P2L2/ST 1 1 10.41 10.41 FOLLICULAR CYST 
11 VIJAYA 40 6135 PAIN ABDOMEN REG P3L2/ST 1 1 18.64 18.64 SC 
12 PAIAZ 34 6669 PAIN ABDOMEN REG P2L2/ST 1 3 10.66 31.98 DERMOID 
13 MALARVILI 35 6147 PAIN ABDOMEN REG P1A1 1 1 21.59 21.59 SC 
14 CHELLAMAL 37 6961 PAIN ABDOMEN REG P2L1/ST 1 3 64.9 194.7 SC 
15 BAKIYAM 56 1981 DISTENTION MNP-13 NG 3 1 101.41 304.23 PSCC 
16 RAJESWARI 60 6753 DISTENTION MNP-5 P6L3 3 3 52.6 473.4 MC  
17 PACHAIAMMA 45 6858 PMB MNP-2 P3L3/ST 3 3 96.15 865.35 SC 
18 MARY 45 7551 DISTENTION REG P3L3 1 1 10.3 10.3 
CHYLOLYMPHATIC 
CYST 
19 PREMA 40 7537 PAIN ABD REG P2L2 1 3 49.36 148.08 SC 
20 SAVITRI 36 9070 PAIN ABD REG P2L2/ST 1 1 72.83 72.83 SC 
21 
POONGAVANA
M 60 7182 DISTENTION MNP-14 P6L4/ST 3 3 17.39 156.51 FIBROTHECOMA 
22 AJIMA 31 3056 PAIN ABD,  REG P2L2 1 1 18.62 18.62 SC 
23 PUSPA 45 8504 PAIN ABD,  REG P3L3 1 3 81.8 245.4 SC 
24 MUNIYAMAL 60 4652 PAIN ABD,  MNP-9 P3L3 3 3 7.82 70.38 FIBROTHECOMA 
25 VIJAYA 40 6743 PAIN ABD REG P3L2 1 1 87.19 87.19 SC 
26 DHARANI 45 8430 PAIN ABD REG P2L2/ST 1 1 62.66 62.66 SC 
27 
DHANALAKSH
MI 43 7747 DISTENTION REG P2L3/ST 1 3 59.37 178.11 SC 
28 USHA 34 8683 PAIN ABD REG P3L2 1 3 16.16 48.48 DERMOID 
29 BANUMATHY 60 8184 DISTENTION MNP-12 P2L1/ST 3 3 84.91 764.19 SC 
30 PARVATHY 55 10238 
PAIN ABD, 
DISTENTION MNP-6 NG 3 3 12.03 108.27 MCC 
31 RAMAMANI 50 7745 DISTENTION REG P5L2 1 3 54.29 162.87 PSC 
32 JAYALAKSMI 42 10336 PAIN ABD REG P3L3 1 1 29.56 29.56 SC 
33 
CHINNAPONN
U 34 11996 PAIN ABD REG P2L2/ST 1 3 12.61 37.83 DERMOID 
34 CHITRA 34 11983 DISTENTION REG P3L2/ST 1 1 83.27 83.27 MC 
35 KALIAMMA 50 9078 PAIN ABD IRREG P5L5/ST 1 1 75.27 75.27 SC 
36 VALARMATHY 35 9479 PAIN ABD IRREG P2L2 1 3 43.65 130.95 SC 
37 JAYA 48 21324 PAIN ABD, MNP-1 P2L2/ST 3 1 9.64 28.92 GCT 
38 GOMATHY 40 10971 DISTENTION IRREG P2L2 1 3 38.36 115.08 MCC 
39 
CHINNAAMMA
L 48 12140 DISTENTION IRREG P4L2/ST 1 3 731.84 
2195.5
2 EAC 
40 DEEPAVATHY 37 14220 PAIN ABD REG P2L2/ST 1 3 259.12 777.36 APST 
41 RANI 36 13513 PAIN ABD REG P1L2 1 1 10.59 10.59 DERMOID 
42 CHANDRAMA 66 12700 DISTENTION MNP-16 P3L3/ST 3 3 79.31 713.79 EAC 
43 KALAIVANI 54 13605 DISTENTION MNP-3 P2L2/ST 3 3 826.72 
7440.4
8 PSCC 
44 JEBARANI 38 14930 PAIN ABD REG P2L2 1 1 8.51 8.51 DERMOID 
45 MANONMANI 55 17721 DISTENTION IRREG P3L3 1 1 91.9 91.9 MCC 
46 RUCMANI 35 14161 DISTENTION REG P1L1 1 1 103.89 103.89 SC 
47 KALAIARASI 39 16361 DISTENTION IRREG P2L2 1 1 81.3 81.3 MC 
48 GAJALAKSMI 49 13059 DISTENTION IRREG P2L1 1 3 285 855 PSCC  
49 RABECA 50 14209 DISTENTION MNP-4 P4L2/ST 3 3 35 315 PSCC 
50 GAYATHRI 30 17664 PAIN ABD REG NG 1 1 9.48 9.48 DERMOID 
51 KUMARI 47 15864 PAIN ABD REG P2L2 1 1 6.7 6.7 
SIMPLE SEROUS 
CYST 
52 MEERABAI 39 16840 PAIN ABD REG P2L2 1 1 8.48 8.48 DERMOID 
53 PARVATHY 40 16000 DISTENTION REG P3L3/ST 1 1 13.48 13.48 MC 
54 VALLI 42 17100 PAIN ABD REG P4L3/ST 1 1 49.13 49.13 SC 
55 SULOCHANA 62 14469 DISTENTION MNP-10 P6L5 3 1 46.28 138.84 SC 
56 VANITHA 33 17999 PAIN ABD REG P1L1 1 3 29.26 87.78 DERMOID 
57 KANNAMAL 32 16858 PAIN ABD IRREG P2L2/ST 1 3 37.1 111.3 SC 
58 PUSPA 48 23026 DISTENTION IRREG P3L3/ST 1 1 57.4 57.4 SC 
59 
ANNAPOORAN
I 33 19219 PAIN ABD REG P2L2/ST 1 1 26.99 26.99 SC 
60 VANAJA 32 20054 PAIN ABD REG P2L2/ST 1 1 8.35 8.35 
SIMPLE SEROUS 
CYST 
61 NATHIYA 35 19926 PAIN ABD REG P1A2 1 1 59.62 59.62 SC 
62 VALARMATHY 36 19245 PAIN ABD REG P3L2/ST 1 1 6.99 6.99 SC 
63 SARASWATHY 38 18468 PAIN ABD REG NG 1 1 9.15 9.15 DERMOID 
64 JEYALAKSMI 34 19409 
PAIN 
ABD;DISTENTION REG NG 1 3 82.76 248.28 SCC 
  
65 SARASWATHY 31 21226 DISTENTION IRREG P2L2/ST 1 1 14.74 14.74 MC 
66 MUTHUDEVI 55 19650 DISTENTION MNP-6 P2L2/ST 3 1 20.13 60.39 MC 
67 
SAMPOORAN
AM 57 19568 DISTENTION MNP-6 P3L2/ST 3 1 30.89 92.67 MC 
68 SASIKALA 35 21989 PAIN ABD REG P2L2 1 1 63.79 63.79 SC 
69 LILLY 32 21380 DISTENTION IRREG P2L2A1 1 3 173.56 520.68 APST 
70 VENNILA 34 21149 PAIN ABD REG P2L1A2 1 1 62.59 62.59 SC 
71 LAKSMI 31 22852 PAIN ABD REG P2L2/ST 1 1 47.81 47.81 SC 
72 PREMA 30 23545 PAIN ABD REG P2L2/ST 1 3 10.17 30.51 DERMOID 
73 KALAIVANI 32 23903 PAIN ABD IRREG NG 1 3 9.43 28.29 STRUMA OVARI 
74 SATHYAVANI 30 23651 PAIN ABD REG P3L3/ST 1 1 16.86 16.86 
SIMPLE SEROUS 
CYST 
75 AMUDHA 33 24224 PAIN ABD IRREG P2L2/ST 1 1 71.48 71.48 SC 
76 
CHINNAPONN
U 47 24214 DISTENTION IRREG P3L3/ST 1 3 156.8 470.4 PSCC 
77 THARA 48 23885 DISTENTION IRREG P3L2 1 3 185.6 556.8 EAC 
78 SELVI 41 22643 DISTENTION MNP-1 P3L3 3 3 12.3 110.7 MC 
79 AMUDHA 30 25784 PAIN ABD IRREG P2L2/ST 1 3 13.6 40.8 MC 
80 JAYALAKSMI 38 26210 PAIN ABD REG P3L3/ST 1 1 15.55 15.55 DERMOID 
81 ESTHER 70 22136 DISTENTION MNP-22 P5L4 3 3 13.4 120.6 SC 
82 ANJALI 45 27035 DISTENTION IRREG P3L3 1 3 14.62 43.86 MC 
83 BHAVANI 34 28365 PAIN ABD REG P1L1 1 1 13.73 13.73 DERMOID 
84 SARASWATHY 33 27965 PAIN ABD REG P2L2/ST 1 1 9.03 9.03 DERMOID 
85 SUBAITHA 58 27585 DISTENTION MNP-3 P3L3 3 1 72 216 MCC 
86 MAHESWARI 32 30007 DISTENTION REG P2L2/ST 1 3 12.48 37.44 MC 
87 SARASWATHY 34 31914 PAIN ABD REG P3L2/ST 1 1 39.71 39.71 SC 
88 SUNDARI 31 30927 PAIN ABD REG P3L3 1 1 11.57 11.57 DERMOID 
89 VIJAYA 35 32254 DISTENTION IRREG P2L2/ST 1 3 204.76 614.28 SCC 
90 JENNIFER 32 34054 PAIN ABD REG P1L0 1 1 55.39 55.39 SC 
91 CHANDRA 49 33381 PAIN ABD REG P4L4/ST 1 1 8.9 8.9 DERMOID 
92 CHINATHAI 55 33078 PAIN ABD MNP-3 P4L3/ST 3 1 10.63 31.89 DERMOID 
93 KULLAMAL 70 33232 PAIN ABD MNP-20 P5L5/ST 3 1 11.7 35.1 SC 
94 PARIMALA 42 33395 DISTENTION REG P3L3/ST 1 1 49.59 49.59 SC 
95 DEEPA 41 30377 PAIN ABD REG NG 1 3 380.1 1140.3 PSCC 
96 VALLI 43 37264 PAIN ABD REG P3L2/ST 1 3 7.14 21.42 DERMOID 
97 LAKSMI 60 35285 DISTENTION MNP-6 NG 3 1 73.12 219.36 SC 
98 AMUL 68 19205 PAIN ABD MNP-10 P2L2/ST 3 3 6.99 62.91 MC 
99 LOGANAYAKI 30 21141 PAIN ABD IRREG NG 1 1 11.19 11.19 SC 
100 AMUDHA 51 21874 DISTENTION MNP-2 NG 3 3 498.4 4485.6 SCC 
101 DEVAKI 74 20683 DISTENTION MNP-17 NG 3 3 44.23 398.07 SCC 
102 LAKSMI 46 37811 PAIN MNP-2 NG 3 1 236.53 709.59 EAC 
103 SUMATHY 30 23487 PAIN ABD REG P1L1 1 1 29.47 29.47 SC 
104 REVATHY 39 24958 PAIN ABD IRREG P3L2/ST 1 1 20.12 20.12 SC 
105 BHARATHI 31 23532 PAIN ABD REG P2L2 1 3 24.22 72.66 PSC 
106 SUDHA 55 14399 
PAIN 
ABD,DISTENTION MNP-5 NG 3 1 50.22 150.66 MC 
107 NALINI 50 13732 PAIN ABD REG P5L2 1 1 20.74 20.74 SC 
108 PALIAMMAL 30 25317 PAIN ABD REG P2L2/ST 1 1 57.36 57.36 SC 
109 SELVI 45 12934 
PAIN ABD, 
DISTENTION IRREG P2L2A1 1 1 14.72 14.72 MC 
110 SASIKALA 53 15600 PAIN ABD MNP-2 P4L3/ST 3 1 24.65 73.95 SC 
111 ROOPAVATHY 32 15059 PAIN ABD REG NG 1 3 12.79 38.37 DERMOID 
112 ARCHANA 30 25920 PAIN ABDOMEN IRREG P2L2/ST 1 1 10.41 10.41 corpus luteal cyst 
113 SELVI 42 29563 PAIN ABDOMEN REG P3L2/ST 1 1 19.82 19.82 SC 
114 GEETHA 31 16669 PAIN ABDOMEN REG P2L2/ST 1 3 9.39 28.17 DERMOID 
115 SAROJA 33 26462 PAIN ABDOMEN REG P1A1 1 1 24.65 24.65 SC 
116 
SAMPOORNA
M 36 26961 PAIN ABDOMEN REG P2L1/ST 1 3 63.86 191.58 SC 
117 MADHUMITA 54 21981 DISTENTION MNP-2 NG 3 1 121.8 365.4 PSCC 
118 RAJESWARI 59 26753 DISTENTION MNP-5 P6L3 3 3 48.32 434.88 
malignant brenner 
tumor 
119 
VIJAYALAKSH
MI 47 26858 PMB MNP-2 P3L3/ST 3 3 90.45 814.05 SC 
120 GAYATHRI 43 27551 DISTENTION REG P3L3 1 1 11.06 11.06 MC 
121 TAMILARASI 45 27537 PAIN ABD REG P2L2 1 3 47.91 143.73 SC 
122 ANDAL 35 29070 PAIN ABD REG P2L2/ST 1 1 75.98 75.98 SC 
123 
VIJAYAKAKSH
MI 60 27182 DISTENTION MNP-14 P6L4/ST 3 3 420.64 
3785.7
6 PSCC 
124 AMUL 31 33056 PAIN ABD,  REG P2L2 1 1 21.86 21.86 SC 
125 JOTHI 44 28504 PAIN ABD,  REG P3L3 1 3 82.01 246.03 SC 
126 VALLIAMMAL 62 30124 PAIN ABD,  MNP-9 P3L3 3 3 9.44 84.96 FIBROTHECOMA 
127 SUSILA 41 26743 PAIN ABD REG P3L2 1 1 89.11 89.11 SC 
128 BABY 43 28430 PAIN ABD REG P2L2/ST 1 1 60.74 60.74 SC 
129 SASIKALA 45 27747 DISTENTION REG P2L3/ST 1 3 58.82 176.46 SC 
130 THILAGA 32 28683 PAIN ABD REG P3L2 1 3 15.63 46.89 DERMOID 
131 DESAMAL 62 28184 DISTENTION MNP-12 P2L1/ST 3 3 84.63 761.67 SC 
132 SUNDARI 56 20154 
PAINABD, 
DISTENTION MNP-6 NG 3 3 14.24 128.16 MCC 
133 ANITHA 53 17745 DISTENTION REG P5L2 1 3 55.85 167.55 PSC 
134 JEEVITHA 43 20143 PAIN ABD REG P3L3 1 1 28.99 28.99 SC 
135 KALPANA 37 21996 PAIN ABD REG P2L2/ST 1 3 11.95 35.85 DERMOID 
  
136 JAMUNA 49 29951 DISTENTION MNP-2 NG 3 3 498.4 4485.6 SCC 
137 LAKSMI 51 29078 PAIN ABD IRREG P5L5/ST 1 1 76.06 76.06 SC 
138 MAHESWARI 32 19479 PAIN ABD IRREG P2L2 1 3 44.82 134.46 SC 
139 MANJULA 49 21378 PAIN ABD, MNP-1 P2L2/ST 3 1 10.9 32.7 GCT 
140 RADHIKA 43 10959 DISTENTION IRREG P2L2 1 3 40.28 120.84 MCC 
141 DEVI 49 12197 DISTENTION IRREG P4L2/ST 1 3 727.18 
2181.5
4 EAC 
142 HEMAVATHI 30 14631 PAIN ABD REG P2L2/ST 1 3 263.59 790.77 APST 
143 CHITRA 34 23513 PAIN ABD REG P1L2 1 1 11.53 11.53 DERMOID 
144 MARIAMMAL 67 12745 DISTENTION MNP-16 P3L3/ST 3 3 81.43 732.87 EAC 
145 MARUDAYE 52 13684 DISTENTION MNP-3 P2L2/ST 3 3 832.64 
7493.7
6 PSCC 
146 ANUPRIYA 32 14984 PAIN ABD REG P2L2 1 1 9.62 9.62 DERMOID 
147 POOVAYEE 56 17428 DISTENTION MNP-2 P3L3 3 1 48.91 146.73 MCC 
148 LAKSMI 34 14494 DISTENTION REG P3L3 1 1 101.78 101.78 SC 
149 RENUGA 38 16364 DISTENTION IRREG P4L2/ST 1 1 83.74 83.74 MC 
150 MAHESWARI 52 13073 DISTENTION MNP-2 P1L1 3 3 284.86 
2563.7
4 PSCC 
151 NAGAMMAL 51 14251 DISTENTION MNP-4 P4L2/ST 3 3 56.92 512.28 PSCC 
152 SUMATHI 31 17693 PAIN ABD REG NG 1 1 9.72 9.72 DERMOID 
153 LATHA 45 15827 PAIN ABD REG P2L2 1 1 10.67 10.67 
SIMPLE SEROUS 
CYST 
154 SARASWATHY 32 29643 PAIN ABD IRREG NG 1 1 45.75 45.75 SC 
155 PARVATHY 43 16835 DISTENTION REG P3L3/ST 1 1 15.72 15.72 MC 
156 JAMEELA 41 17638 PAIN ABD REG P4L3/ST 1 1 50.26 50.26 SC 
157 SABEENA 63 14542 DISTENTION MNP-10 P6L5 3 1 47.12 141.36 SC 
158 VIJAYA 30 17954 PAIN ABD REG P1L1 1 3 26.98 80.94 DERMOID 
159 SARITHA 33 23858 PAIN ABD IRREG P2L2/ST 1 3 38.52 115.56 SC 
160 RAMAYE 50 27473 DISTENTION IRREG P3L3/ST 1 1 58.39 58.39 SC 
161 AMMU 33 21921 PAIN ABD REG P2L2/ST 1 1 29.69 29.69 SC 
162 JEYANTHI 35 25431 PAIN ABD REG P2L2/ST 1 1 13.24 13.24 
SIMPLE SEROUS 
CYST 
163 HEMALATHA 30 21926 PAIN ABD REG P1A2 1 1 60.41 60.41 SC 
164 ANITHA 34 19263 PAIN ABD REG P3L2/ST 1 1 17.42 17.42 SC 
165 SHENBAGAM 32 18424 PAIN ABD REG NG 1 1 7.22 7.22 DERMOID 
166 PATTU 36 19449 
PAIN 
ABD;DISTENTION REG NG 1 3 83.33 249.99 SCC 
167 DEVI 35 21274 DISTENTION IRREG P2L2/ST 1 1 16.82 16.82 MC 
168 ARUNAMMA 56 19627 DISTENTION MNP-6 P2L2/ST 3 1 89.53 268.59 PSCC 
169 AMARAVATHI 57 19524 DISTENTION MNP-6 P3L2/ST 3 1 29.18 87.54 MC 
170 NAGARANI 37 21934 PAIN ABD REG P2L2 1 1 63.99 63.99 SC 
171 ANNIE 34 21346 DISTENTION IRREG P2L2A1 1 3 169.83 509.49 APST 
172 KANMANI 30 21373 PAIN ABD REG P2L1A2 1 1 64.16 64.16 SC 
173 VASANTHA 31 22825 PAIN ABD REG P2L2/ST 1 1 42.68 42.68 SC 
174 ANITHA 34 23535 PAIN ABD REG P2L2/ST 1 3 9.35 28.05 DERMOID 
175 UMA 53 23905 PAIN ABD IRREG NG 1 3 10.98 32.94 STRUMA OVARI 
176 PUNITHA 32 23693 PAIN ABD REG P3L3/ST 1 1 15.83 15.83 
SIMPLE SEROUS 
CYST 
177 SANGEETHA 35 24252 PAIN ABD IRREG P2L2/ST 1 1 69.49 69.49 SC 
178 SHALINI 45 24287 DISTENTION IRREG P3L3/ST 1 3 198.74 596.22 PSCC 
179 SARGUNAM 49 23855 DISTENTION MNP-1 P3L2 3 3 189.52 
1705.6
8 EAC 
180 KAVITHA 52 22697 DISTENTION MNP-2 P3L3 3 3 14.73 132.57 MC 
181 SUMITHRA 33 25372 PAIN ABD IRREG P2L2/ST 1 3 14.63 43.89 MC 
182 VANITHA 37 26107 PAIN ABD REG P3L3/ST 1 1 14.75 14.75 DERMOID 
183 RAJATHI 68 22197 DISTENTION MNP-22 P5L4 3 3 16.83 151.47 SC 
184 PORSELVI 45 27096 DISTENTION IRREG P3L3 1 3 19.42 58.26 MC 
185 SUDHA 30 28332 PAIN ABD REG P1L1 1 1 12.62 12.62 DERMOID 
186 SUMATHI 35 27949 PAIN ABD REG P2L2/ST 1 1 8.98 8.98 DERMOID 
187 ANANDHI 57 27515 DISTENTION MNP-3 P3L3 3 1 75.2 225.6 MCC 
188 MEGALA 31 30105 DISTENTION REG P2L2/ST 1 3 14.05 42.15 MC 
189 VASUKI 30 31938 PAIN ABD REG P3L2/ST 1 1 41.96 41.96 SC 
190 NALINI 36 30904 PAIN ABD REG P3L3 1 1 11.53 11.53 DERMOID 
191 PRABAVATHI 33 32178 DISTENTION IRREG P2L2/ST 1 3 285.19 855.57 SCC 
192 PANDIAMMAL 32 34028 PAIN ABD REG P1L0 1 1 58.93 58.93 SC 
193 GOWRI 45 33265 PAIN ABD REG P4L4/ST 1 1 10.41 10.41 DERMOID 
194 BANUMATHY 57 33102 PAIN ABD MNP-3 NG 3 1 94.62 283.86 PSCC 
195 INDIRANI 68 33219 PAIN ABD MNP-20 P5L5/ST 3 1 21.54 64.62 SC 
196 SELVI 45 33358 DISTENTION REG P3L3/ST 1 1 59.42 59.42 SC 
197 KOUSALYA 43 30357 PAIN ABD REG NG 1 3 417.88 
1253.6
4 PSCC 
198 USHA 41 37246 PAIN ABD REG P3L2/ST 1 3 8.42 25.26 DERMOID 
199 LAKSMI 62 35252 DISTENTION MNP-6 NG 3 1 71.83 215.49 SC 
200  YASMIN 65 19272 PAIN ABD MNP-10 P2L2/ST 3 3 11.21 100.89 MCC 
 
 
  
KEY TO THE MASTER CHART 
RMI  - Risk of Malignancy Index 
USG  - Ultrasonogram 
NG  - NulliGravida 
REG  - Regular 
IRREG - Irregular 
PMB  - Post Menopausal Bleeding 
ABD  - Abdomen 
MNP  - Menopause 
P  - Para 
L  - Live 
A  - Abortion 
ST  - Sterlised 
HPE  - Histopathological Examination 
SC  - Serous Cystadenoma 
MC  - Mucinous Cystadenoma 
PSC  - Papillary serous cystadenoma 
PSCC  - Papillary Serous Cystadeno Carcinoma 
MCC  - Mucinous Cystadeno Carcinoma 
SCC  - Serous Cystadeno Carcinoma 
GCT  - Granulosa Cell Tumor 
EAC  - Endometroid Adeno Carcinoma 
APST  - Atypical Proliferative Seromucinous tumor 
MENO - Menopausal 
  
  
ABBREVIATIONS 
 
USG   Ultrasonagraphy 
RMI   Risk of Malignancy Index 
CA  125  Cancer Antigen 125 
PI   Pulsality Index 
ROC   Receiver Operating characteristic Curve 
PPV   Positive Predictive Value 
NPV   Negative Predictive Value 
HCG   Human Chorionic Gonadotropin 
GIT   Gastro Intestinal Tract 
HPE   Histopathological Examination 
 
  
  
 
